var title_f29_42_30368="Parasternal long view tamponade";
var content_f29_42_30368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/67599/Parast_long_view_tamp_movie.mp4?title=Parasternal+long+view+tamponade\" style=\"width:496px;height:320px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Parasternal long view of cardiac tamponade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This video clip shows a large pericardial effusion causing tamponade as seen from a parasternal long axis view.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30368=[""].join("\n");
var outline_f29_42_30368=null;
var title_f29_42_30369="T cell receptor";
var content_f29_42_30369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    The T cell receptor (TCR) complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic illustration of TCR alpha and beta polypeptide chains linked to the CD3 molecular complex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Diseases of Immunity. In: Robbins pathologic basis of disease, 6th ed, Cotran, RS, Kumar, V, Collins, T (Eds), W.B. Saunders Company, Philadelphia 1999; p.188. Fig 7-1. Copyright &copy; 1999 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30369=[""].join("\n");
var outline_f29_42_30369=null;
var title_f29_42_30370="Patient information: Motion sickness (The Basics)";
var content_f29_42_30370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/39/1650\">",
"         Patient information: Morning sickness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/57/28562\">",
"         Patient information: Nausea and vomiting in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/54/22371\">",
"         Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/63/37874\">",
"         Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Motion sickness (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/motion-sickness-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H18610597\">",
"      <span class=\"h1\">",
"       What is motion sickness?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Motion sickness is a condition that causes nausea, dizziness, and other problems. It happens to people when they are on a boat, in a car, on a carnival ride, or in some other situation in which something is moving them. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18610612\">",
"      <span class=\"h1\">",
"       What are the symptoms of motion sickness?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Dizziness",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Belching",
"       </li>",
"       <li>",
"        Making more saliva than usual",
"       </li>",
"       <li>",
"        Warmth",
"       </li>",
"       <li>",
"        Sweating",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18610627\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You might feel better if you keep your eyes on the outside world while you are in motion. For example, if you are in a car, sit in the front and look in the direction you are moving; if you are on a boat, stay on the deck and look to the horizon. This helps make what you see match the movement you are feeling, and so you are less likely to feel sick.",
"     </p>",
"     <p>",
"      You should also avoid reading, watching a movie, or looking at things close to you inside the vehicle you are riding.",
"     </p>",
"     <p>",
"      Sometimes, lying on your back can ease motion sickness.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18610642\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you know you get motion sickness and you need to be on a boat or in a car, see your doctor or nurse. He or she can help you figure out how to manage your problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18610657\">",
"      <span class=\"h1\">",
"       How is motion sickness treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are a number of medicines that can help prevent and treat motion sickness. In general, these medicines work best if you take them before symptoms start. Many have the draw-back of making you feel sleepy. &nbsp;",
"     </p>",
"     <p>",
"      Non-prescription (over-the-counter) medicines include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?33/50/34596?source=see_link\">",
"         Dimenhydrinate",
"        </a>",
"        (sample brand names: Dramamine&reg;, TripTone&reg;)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/60/25537?source=see_link\">",
"         Diphenhydramine",
"        </a>",
"        (sample brand name: Benadryl&reg;)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?13/33/13844?source=see_link\">",
"         Meclizine",
"        </a>",
"        (sample brand names: Antivert&reg;, Bonine&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The most commonly used prescription medicines include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?37/47/38640?source=see_link\">",
"         Scopolamine",
"        </a>",
"        patch (brand names: Scopace",
"        <sup>",
"         TM",
"        </sup>",
"        , Transderm Scop&reg;) &ndash; This is a patch that can stay on your skin for 3 days.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?2/47/2806?source=see_link\">",
"         Promethazine",
"        </a>",
"        (sample brand names: Phenadoz&reg;, Promethegan&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other treatments for motion sickness include ginger, physical therapy, and acupressure.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18610672\">",
"      <span class=\"h1\">",
"       Can motion sickness be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The same medicines used to treat motion sickness can also prevent it. You can buy some of these medicines without a prescription. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18610686\">",
"      <span class=\"h1\">",
"       What if I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women who are pregnant are much more likely than other people to get motion sickness. Luckily, there are medicines that pregnant women can safely take to prevent and treat the condition. Ask your doctor which medicines are safe for you and your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18610701\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=see_link\">",
"       Patient information: Nausea and vomiting in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/39/1650?source=see_link\">",
"       Patient information: Morning sickness (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/63/37874?source=see_link\">",
"       Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=see_link\">",
"       Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/42/30370?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16731 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.55.141.10-024AF9ABBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30370=[""].join("\n");
var outline_f29_42_30370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18610597\">",
"      What is motion sickness?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18610612\">",
"      What are the symptoms of motion sickness?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18610627\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18610642\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18610657\">",
"      How is motion sickness treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18610672\">",
"      Can motion sickness be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18610686\">",
"      What if I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18610701\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/39/1650?source=related_link\">",
"      Patient information: Morning sickness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=related_link\">",
"      Patient information: Nausea and vomiting in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=related_link\">",
"      Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/63/37874?source=related_link\">",
"      Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_42_30371="Transperineal fistula repair6";
var content_f29_42_30371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The puborectalis fibers are reapproximated in the midline, providing an additional reinforcing layer between the anterior rectal and posterior vaginal walls.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30371=[""].join("\n");
var outline_f29_42_30371=null;
var title_f29_42_30372="Topical tretinoin (topical all trans retinoic acid): Patient drug information";
var content_f29_42_30372=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Topical tretinoin (topical all trans retinoic acid): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"     see \"Topical tretinoin (topical all trans retinoic acid): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/10/43171?source=see_link\">",
"     see \"Topical tretinoin (topical all trans retinoic acid): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atralin&trade;;",
"     </li>",
"     <li>",
"      Avita&reg;;",
"     </li>",
"     <li>",
"      Refissa&reg;;",
"     </li>",
"     <li>",
"      Renova&reg;;",
"     </li>",
"     <li>",
"      Retin-A Micro&reg;;",
"     </li>",
"     <li>",
"      Retin-A&reg;;",
"     </li>",
"     <li>",
"      Tretin-X&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rejuva-A&reg;;",
"     </li>",
"     <li>",
"      Renova&reg;;",
"     </li>",
"     <li>",
"      Retin-A Micro&reg;;",
"     </li>",
"     <li>",
"      Retin-A&reg;;",
"     </li>",
"     <li>",
"      Retinova&reg;;",
"     </li>",
"     <li>",
"      Stieva-A;",
"     </li>",
"     <li>",
"      Vitamin A Acid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692099",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin harmed by the sun and some skin cancers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691362",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the number of wrinkles and liver spots. It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tretinoin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are sunburned.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have eczema, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin may look worse before it looks better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sunburn.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696229",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wait 30 minutes before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Practice good skin care and avoid the sun.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699267",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect gel from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11118 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30372=[""].join("\n");
var outline_f29_42_30372=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230490\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230491\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024654\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024653\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024658\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024659\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024661\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024656\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024657\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024662\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024663\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=related_link\">",
"      Topical tretinoin (topical all trans retinoic acid): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/10/43171?source=related_link\">",
"      Topical tretinoin (topical all trans retinoic acid): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_42_30373="Recombinant human factor VIIa: Drug information";
var content_f29_42_30373=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Recombinant human factor VIIa: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/40/10884?source=see_link\">",
"    see \"Recombinant human factor VIIa: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/18/44324?source=see_link\">",
"    see \"Recombinant human factor VIIa: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10053630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NovoSeven&reg; RT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Niastase&reg;;",
"     </li>",
"     <li>",
"      Niastase&reg; RT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F169459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antihemophilic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F169445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. administration only:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hemophilia A or B with inhibitors:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Bleeding episodes:",
"     </i>",
"     90 mcg/kg every 2 hours until hemostasis is achieved or until the treatment is judged ineffective. Doses between 35-120 mcg/kg have been used successfully in clinical trials. The dose, interval, and duration of therapy may be adjusted based upon the severity of bleeding and the degree of hemostasis achieved. For patients experiencing severe bleeds, dosing should be continued at 3- to 6-hour intervals after hemostasis has been achieved and the duration of dosing should be minimized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Surgical interventions:",
"     </i>",
"     90 mcg/kg immediately before surgery; repeat at 2-hour intervals for the duration of surgery. Continue every 2 hours for 48 hours, then every 2-6 hours until healed for minor surgery; continue every 2 hours for 5 days, then every 4 hours until healed for major surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Congenital factor VII deficiency:",
"     </b>",
"     Bleeding episodes and surgical interventions: 15-30 mcg/kg every 4-6 hours until hemostasis is achieved. Doses as low as 10 mcg/kg have been effective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acquired hemophilia:",
"     </b>",
"     70-90 mcg/kg every 2-3 hours until hemostasis is achieved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intracerebral hemorrhage (ICH) (warfarin-related) (unlabeled use; Freeman, 2004; Ilyas, 2008):",
"     </b>",
"     10-100 mcg/kg (see",
"     <b>",
"      \"Note\"",
"     </b>",
"     below) administered concurrently with I.V. vitamin K (to correct the nonfactor VII coagulation factors).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Lower doses (10-20 mcg/kg) are generally preferred given the higher risk of thromboembolic complications with higher doses; response is highly variable; monitor INR frequently after administration since rebound increases in INR occur quickly given the short half-life of rFVIIa; duration of INR correction is dose dependent. Routine use as a sole agent is not recommended for warfarin-related ICH (Morgenstern, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of refractory bleeding after cardiac surgery in nonhemophiliac patients:",
"     </b>",
"     Dosing not established; doses in the range of 35-70 mcg/kg have been recommended based on low-quality evidence (case series, observational studies) (Chapman, 2011; Ferraris, 2011; Karkouti, 2007); in patients with a left ventricular assist device, lower doses (ie, 10-20 mcg/kg) may be preferred to reduce thromboembolic events (Bruckner, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F169454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/18/44324?source=see_link\">",
"      see \"Recombinant human factor VIIa: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hemophilia A or B with inhibitors:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Congenital factor VII deficiency:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acquired hemophilia:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F169446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoSeven&reg; RT: 1 mg [contains polysorbate 80, sodium 0.4 mEq/mg rFVlla, sucrose 10 mg/vial; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoSeven&reg; RT: 2 mg [contains polysorbate 80, sodium 0.4 mEq/mg rFVlla, sucrose 20 mg/vial; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoSeven&reg; RT: 5 mg [contains polysorbate 80, sodium 0.4 mEq/mg rFVlla, sucrose 50 mg/vial; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoSeven&reg; RT: 8 mg [contains polysorbate 80, sodium 0.4 mEq/mg rFVlla, sucrose 80 mg/vial; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F169432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. administration only; bolus over 2-5 minutes. Administer within 3 hours after reconstitution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F169431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bleeding episodes and prevention of bleeding in surgical interventions in patients with either hemophilia A or B  with inhibitors to factor VIII or factor IX, acquired hemophilia, or congenital factor VII deficiency",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5516864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Warfarin-related intracerebral hemorrhage; treatment of refractory bleeding after cardiac surgery in nonhemophiliac patients",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F169457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (2%), bradycardia (1%), edema (1%), hypotension (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (4%), headache (1%), pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (1%), purpura (1%), rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Plasma fibrinogen decreased (2%), disseminated intravascular coagulation (1%), fibrinolysis increased (1%), prothrombin decreased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthrosis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Abnormal renal function (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pneumonia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic shock, angina, angioedema, antibody formation, arterial thrombosis, arterial thrombosis (limb), arthralgia, bowel infarction, cerebral artery occlusion, cerebral infarction and/or ischemia, consumptive coagulopathy, CVA, D-dimer elevation, deep vein thrombosis, fibrin degradation products increased, flushing, hepatic artery thrombosis, hypersensitivity, hypersensitivity reaction, injection site pain, intestinal infarction, I.V. site thrombosis, localized phlebitis, MI, myocardial ischemia, nausea, peripheral ischemia, portal vein thrombosis, pulmonary embolism, renal artery thrombosis, retinal artery embolism, retinal artery thrombosis, shock, thrombophlebitis, thrombosis, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F169435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the FDA-approved labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F169420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Use with caution in patients with known hypersensitivity to mouse, hamster, or bovine proteins, or factor VIIa, or any components of the product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events:",
"     <b>",
"      [U.S. Boxed Warning]: Serious thrombotic events are associated with the use of factor VIIa outside labeled indications. Arterial and venous thrombotic and thromboembolic events, some fatal, following administration of factor VIIa have been reported during postmarketing surveillance. Thrombotic events have also been reported when used within labeled indications.",
"     </b>",
"     All patients receiving factor VIIa should be monitored for signs and symptoms of activation of the coagulation system or thrombosis; thrombotic events may be increased in patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, sepsis, crush injury, or concomitant treatment with prothrombin complex concentrates. Use with caution in patients with an increased risk of thromboembolic complications (eg, coronary heart disease, liver disease, DIC, postoperative immobilization, elderly patients, and neonates). Decreased dosage or discontinuation is warranted with confirmed intravascular coagulation or presence of clinical thrombosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term use: Efficacy with prolonged infusions and data evaluating this agent's long-term adverse effects are limited.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2181984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F169450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16354807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if factor VIIa (recombinant) is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F169436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (NovoSeven RT Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (1): $2.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (1): $2.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $2.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (1): $2.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F169428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for evidence of hemostasis; although the prothrombin time/INR, aPTT, and factor VII clotting activity have no correlation with achieving hemostasis, these parameters may be useful as adjunct tests to evaluate efficacy and guide dose or interval adjustments",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F169437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Novonordisk (MX);",
"     </li>",
"     <li>",
"      NovoSeven (AR, AT, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IN, IT, KP, MT, MY, NL, NO, NZ, PE, PH, PL, PT, RU, SE, SG, SK, TH, TR, TW);",
"     </li>",
"     <li>",
"      Novoseven (MX);",
"     </li>",
"     <li>",
"      Novoseven RT (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F169419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recombinant factor VIIa, a vitamin K-dependent glycoprotein, promotes hemostasis by activating the extrinsic pathway of the coagulation cascade. It replaces deficient activated coagulation factor VII, which complexes with tissue factor and may activate coagulation factor X to Xa and factor IX to IXa. When complexed with other factors, coagulation factor Xa converts prothrombin to thrombin, a key step in the formation of a fibrin-platelet hemostatic plug.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F169434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 103 mL/kg (range: 78-139)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.3 hours (range: 1.7-2.7)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Clearance: 33 mL/kg/hour (range: 27-49)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bruckner BA, DiBardino DJ, Ning Q, et al, \"High Incidence of Thromboembolic Events in Left Ventricular Assist Device Patients Treated With Recombinant Activated Factor VII,\"",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2009, 28(8):785-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/42/30373/abstract-text/19632574/pubmed\" id=\"19632574\" target=\"_blank\">",
"        19632574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman AJ, Blount AL, Davis AT, et al, \"Recombinant Factor VIIa (NovoSeven RT) Use in High Risk Cardiac Surgery,\"",
"      <i>",
"       Eur J Cardiothorac Surg",
"      </i>",
"      , 2011.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/42/30373/abstract-text/21601468/pubmed\" id=\"21601468\" target=\"_blank\">",
"        21601468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Brown JR  Despotis GJ, et al, \"2011 Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines,\"",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2011, 91(3):944-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/42/30373/abstract-text/21353044/pubmed\" id=\"21353044\" target=\"_blank\">",
"        21353044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freeman WD, Brott TG, Barrett KM, et al, &ldquo;Recombinant Factor VIIa for Rapid Reversal of Warfarin Anticoagulation in Acute Intracranial Hemorrhage,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2004, 79(12):1495-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/42/30373/abstract-text/15595332/pubmed\" id=\"15595332\" target=\"_blank\">",
"        15595332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ilyas C, Beyer GM, Dutton RP, et al, &ldquo;Recombinant Factor VIIa for Warfarin-Associated Intracranial Bleeding,&rdquo;",
"      <i>",
"       J Clin Anesth",
"      </i>",
"      , 2008, 20(4):276-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/42/30373/abstract-text/18617125/pubmed\" id=\"18617125\" target=\"_blank\">",
"        18617125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karkouti K, Beattie WS, Crowther MA, et al, \"The Role of Recombinant Factor VIIa in On-Pump Cardiac Surgery: Proceedings of the Canadian Consensus Conference,\"",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 2007, 54(7):573-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/42/30373/abstract-text/17602044/pubmed\" id=\"17602044\" target=\"_blank\">",
"        17602044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayer SA, Brun NC, Begtrup K, et al, &ldquo;Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(20):2127-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/42/30373/abstract-text/18480205/pubmed\" id=\"18480205\" target=\"_blank\">",
"        18480205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayer SA, Brun NC, Begtrup K, et al, &ldquo;Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(8):777-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/42/30373/abstract-text/15728810/pubmed\" id=\"15728810\" target=\"_blank\">",
"        15728810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohr AM, Holcomb JB, Dutton RP, et al, &ldquo;Recombinant Activated Factor VIIa and Hemostasis in Critical Care: A Focus on Trauma,&rdquo;",
"      <i>",
"       Crit Care",
"      </i>",
"      , 2005, 9 (Suppl 5):37-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/42/30373/abstract-text/15693982/pubmed\" id=\"15693982\" target=\"_blank\">",
"        15693982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgenstern LB, Hemphill JC, Anderson C, et al, \"Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association,\"",
"      <i>",
"       Stroke",
"      </i>",
"      , 2010, 41(9):2108-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/42/30373/abstract-text/20651276/pubmed\" id=\"20651276\" target=\"_blank\">",
"        20651276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10155 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30373=[""].join("\n");
var outline_f29_42_30373=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10053630\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169443\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169444\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169459\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169445\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169454\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169446\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881412\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881413\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169430\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169417\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169432\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169431\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5516864\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169457\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169435\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169420\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299309\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220313\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169426\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2181984\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169450\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16354807\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169436\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323142\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169428\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169437\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169419\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169434\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10155\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10155|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/40/10884?source=related_link\">",
"      Recombinant human factor VIIa: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/18/44324?source=related_link\">",
"      Recombinant human factor VIIa: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_42_30374="Atrial tachycardia ECG 3";
var content_f29_42_30374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Atrial tachycardia ECG 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 461px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiographic tracing showing a narrow complex tachycardia with uniform P waves consistent with atrial tachycardia originating from the left superior pulmonary vein. The initial QRS complex shows a normal sinus beat, followed by the development of atrial tachycardia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Peter Kistler.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30374=[""].join("\n");
var outline_f29_42_30374=null;
var title_f29_42_30375="PCLBCL-LT clinical presentation I";
var content_f29_42_30375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68920%7EHEME%2F79655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68920%7EHEME%2F79655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous diffuse large B-cell lymphoma, leg type",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with a primary cutaneous diffuse large B-cell lymphoma, leg type presenting with localized skin tumors on the left leg. Most patients present with red or bluish nodules or tumors on one or both legs, preferentially the lower legs. Ten to 15 percent will develop outside of the lower extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient with a primary cutaneous diffuse large B-cell lymphoma, leg type presenting with extensive skin tumors on the left leg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30375=[""].join("\n");
var outline_f29_42_30375=null;
var title_f29_42_30376="Use of medication nebulizers in children";
var content_f29_42_30376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of medication nebulizers in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/42/30376/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/42/30376/contributors\">",
"     Robert H Moore, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/42/30376/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/42/30376/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/42/30376/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/42/30376/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/42/30376/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/42/30376/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The delivery of aerosolized medication is an important component of treatment for many respiratory disorders in children. Glucocorticoids, bronchodilators, antibiotics, mucus hydration agents, and mucolytic agents can be administered via aerosol.",
"   </p>",
"   <p>",
"    Nebulizer devices are widely used to deliver aerosol therapy, especially in children. A wide variety of nebulizers is available for use in the home and hospital, with varying capacities to deliver drugs to the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinicians must consider how a particular nebulizer performs with the specific drug to be administered to ensure its clinical suitability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of medication in nebulizers for children is presented here. An overview of aerosolized medication delivery in children and the use of pressurized metered dose inhalers are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31014?source=see_link\">",
"     \"Delivery of inhaled medication in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nebulizers are used to provide aerosol therapy to patients too ill or too young to use hand-held devices and in situations where large drug doses are necessary. These devices also are required for some medications available only in liquid form, including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/54/37734?source=see_link\">",
"     pentamidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     ribavirin",
"    </a>",
"    , DNAase, hypertonic saline, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/39/22129?source=see_link\">",
"     tobramycin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The potential benefits of nebulizers need to be balanced with the disadvantages associated with the use of these devices. These include higher costs, longer setup and delivery time, decreased portability, variable nebulizer performance, and (with jet nebulizers) the need for a source of compressed air or oxygen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BASIC TYPES OF NEBULIZERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three types of nebulizers: jet nebulizers, ultrasonic nebulizers, and vibrating mesh (membrane) nebulizers. There are differences in performance among these types of nebulizers and also among nebulizers of the same type produced by various manufacturers. These differences have potential clinical implications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/5\">",
"     5",
"    </a>",
"    ]. Jet nebulizers are the most frequently used form of nebulizer in the clinical setting. The advantages and disadvantages of the jet [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/6-9\">",
"     6-9",
"    </a>",
"    ], ultrasonic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/6,8\">",
"     6,8",
"    </a>",
"    ], and mesh [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] nebulizers are reviewed in the table (",
"    <a class=\"graphic graphic_table graphicRef64982 \" href=\"UTD.htm?43/38/44652\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Jet nebulizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jet nebulizers utilize a driving gas of compressed air or oxygen through a jet, creating a negative pressure which entrains large aerosolized liquid droplets into the gas stream. These particles then are reduced in size by their impaction upon internal baffles, resulting in the generation of smaller, respirable particles of 1 to 5 microm in size [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Aerosolized medication then is delivered through a patient interface, usually a mouthpiece or facemask (",
"    <a class=\"graphic graphic_figure graphicRef75397 \" href=\"UTD.htm?1/7/1137\">",
"     figure 1",
"    </a>",
"    ). Most aerosolized medications are best delivered by this method of nebulization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ultrasonic nebulizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonic nebulizers consist of a power unit and transducer, with or without an electric fan. Electrical energy from the power unit is converted to high-frequency (1.63 megahertz) ultrasonic waves by a piezoelectric element in the transducer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. These ultrasonic waves are transmitted to the surface of the solution to create an aerosol. A fan is used to deliver the aerosol to the patient, or the aerosol is evacuated from the nebulization chamber by the inspiratory flow of the patient. Small volume ultrasonic nebulizers are commercially available for delivery of inhaled bronchodilators. Large volume ultrasonic nebulizers are used for sputum induction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H383507745\">",
"    <span class=\"h2\">",
"     Vibrating mesh nebulizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesh nebulizers use a perforated membrane to generate the aerosol (",
"    <a class=\"graphic graphic_figure graphicRef69736 \" href=\"UTD.htm?37/3/37951\">",
"     figure 2",
"    </a>",
"    ). Electronic nebulizers can generate aerosolized particles that are highly uniform and respirable (mass median diameter of 3.6",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    0.1 microm) and deliver drugs in less than five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Other available vibrating mesh nebulizers include the Aeroneb&reg; (Aerogen),",
"    <span class=\"nowrap\">",
"     MicroAIR&reg;/NE-U22&reg;",
"    </span>",
"    (OMRON), and the I-neb&reg; (Respironics). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31014?source=see_link&amp;anchor=H6#H6\">",
"     \"Delivery of inhaled medication in children\", section on 'Aerosol properties'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FACTORS AFFECTING JET NEBULIZER PERFORMANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jet nebulizers are the most commonly used type of nebulizer in most countries, because of their lower cost and other considerations described above. An effective nebulizer should deliver at least 50 percent of the total dose as respirable aerosol within 10 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/12\">",
"     12",
"    </a>",
"    ]. However, nebulizer performance can vary greatly based upon a number of factors (",
"    <a class=\"graphic graphic_table graphicRef58515 \" href=\"UTD.htm?32/24/33163\">",
"     table 2",
"    </a>",
"    ). Conventional jet nebulizers are highly inefficient because of output lost during exhalation during normal breathing, and because more than 90 percent of the primary droplets become trapped on the baffles or internal structures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, conventional jet nebulizers produce a constant flow rate during aerosolization, leading to further drug wastage and inefficiency. Enhanced jet nebulizers have been designed that address specific delivery issues. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Enhanced jet nebulizer designs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nebulization time",
"      </strong>",
"      &mdash; The majority of nebulized dose is delivered during the first five minutes in most cases [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/14\">",
"       14",
"      </a>",
"      ], and little addition benefit is gained by extending nebulization time beyond 5 to 10 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/9\">",
"       9",
"      </a>",
"      ]. Furthermore, aerosol output drops dramatically and further nebulization is unproductive once sputtering begins [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/15\">",
"       15",
"      </a>",
"      ]. Continuous nebulization is employed in the management of acute severe asthma in children and is discussed below. (See",
"      <a class=\"local\" href=\"#H1352583\">",
"       'Continuous nebulization'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Chamber design",
"      </strong>",
"      &mdash; Nebulizers vary widely in the ability to efficiently aerosolize medications and generate aerosol particles in the \"respirable range,\" with total lung deposition of starting medication ranging from approximately 2 percent up to 20 percent or greater with more efficient nebulizers [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/4,5,16,17\">",
"       4,5,16,17",
"      </a>",
"      ]. The efficiency also varies as a function of patient age. As an example, the mean total lung deposition of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      delivered using a breath-enhanced, open-vent-assisted nebulizer expressed as a percentage of starting dose was 5 percent in children younger than four years of age and 11 percent in children four to nine years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Breath-enhanced open-vent nebulizer'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Driving gas",
"      </strong>",
"      &mdash; The fraction of particles in the respirable range also is altered by the flow rate of the driving air or oxygen, with flow rates of 8 liters per minute providing optimal mass median aerodynamic diameter (MMAD) of the aerosol particles, aerosol volumes, and nebulization times when using conventional small volume nebulizers [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/5,7,18\">",
"       5,7,18",
"      </a>",
"      ]. For these nebulizers, decreasing the driving flow rate from 8",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      to 6",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      may reduce the output of respirable particles by 25 to 30 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/19\">",
"       19",
"      </a>",
"      ]. However, many home compressors are not capable of delivering flow rates this high, resulting in a larger MMAD of the aerosol particles. Alternatively, breath-enhanced nebulizers function efficiently at driving flow rates of 3 to 5",
"      <span class=\"nowrap\">",
"       L/min,",
"      </span>",
"      making them much more effective when used with home compressors [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/20\">",
"       20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Such variances in output highlight the importance of trying to match recommended nebulizers and medical compressors for the medication being delivered, as indicated in package inserts. For instance, pivotal trials for",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/48/35584?source=see_link\">",
"       budesonide",
"      </a>",
"      inhalation suspension used Pari&reg; nebulizers and compressors to provide optimal drug delivery. For some drugs, such as short-acting beta agonists, there currently are no recommendations for specific nebulizers or compressors. In addition, in the hospital setting, the set flow rate may not reflect the true flow exiting the nebulizer when using a dry gas source to drive the nebulizer. This can reduce the flow rate by up to 2",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      due to inadequate back pressure compensation of the flow meter [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/21\">",
"       21",
"      </a>",
"      ] and may result in a larger MMAD and decreased pulmonary deposition of the aerosolized agent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/1,19\">",
"       1,19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      To avoid some of the variation in drug delivery seen with jet nebulizers, a suitable alternative for some medications is to switch to metered dose inhalers with valved-holding chambers. These devices are effective for the chronic delivery of inhaled glucocorticoids and the delivery of short-acting beta agonists in acute asthma, including in the emergency department setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link\">",
"       \"The use of inhaler devices in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Finally, the density of the gas powering the nebulizer affects nebulizer performance. As an example, the inhaled mass of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      is significantly reduced when a nebulizer is powered with a mixture of 60 to 80 percent helium and 20 to 40 percent oxygen (heliox). Accordingly, the flow to the nebulizer should be doubled if it is powered with heliox [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/22\">",
"       22",
"      </a>",
"      ]. Heliox may improve aerosol delivery to the lower respiratory tract, because the decrease in density results in the creation of smaller particles; however, the clinical benefit of this approach is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/23-29\">",
"       23-29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=see_link\">",
"       \"Physiology and clinical use of heliox\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dead volume",
"      </strong>",
"      &mdash; Dead volume refers to the residual medication solution remaining in the nebulizer reservoir after therapy. This residual solution is incapable of activating further nebulization, and the amount can vary considerably between different nebulizer models [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/16,30\">",
"       16,30",
"      </a>",
"      ]. The concentration of drug within this dead volume is increased by the evaporation of the solute, such as normal saline, during nebulization. This can lead to considerable drug wastage.",
"      <br/>",
"      <br/>",
"      The amount of wasted drug can be reduced by adjusting the starting volume of nebulizer solution to at least 4 mL, an amount that generally can be administered within 10 minutes using flow rates of 8",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/5,16\">",
"       5,16",
"      </a>",
"      ]. Tapping on the nebulizer chamber during nebulization may further reduce dead volume.",
"     </li>",
"     <li>",
"      <strong>",
"       Physical properties of the solution",
"      </strong>",
"      &mdash; The primary droplet size produced during nebulization is proportional to the viscosity and surface tension of the nebulized liquid, which increase as the solution cools during nebulization, potentially resulting in decreased output and longer nebulization times [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Other factors",
"      </strong>",
"      &ndash; The level of cooperation of the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/31\">",
"       31",
"      </a>",
"      ]; changes in breathing patterns, such as occurs with persistent cough; and type of facemask used [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/32\">",
"       32",
"      </a>",
"      ] may also impact drug delivery. In addition, the filters on the medical compressor units should be changed every approximately six months; failure to do so can affect performance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ENHANCED JET NEBULIZER DESIGNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhancements to the design of jet nebulizers have improved performance and reduced aerosol waste during the exhalation phase (",
"    <a class=\"graphic graphic_picture graphicRef56942 \" href=\"UTD.htm?2/45/2770\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64982 \" href=\"UTD.htm?43/38/44652\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Breath-enhanced open-vent nebulizer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open-vent jet nebulizers incorporate an opening in the reservoir that allows the continuous entrainment of air during nebulization, resulting in increased airflow within the nebulizer chamber, smaller aerosol particle size, shorter nebulization times, and greater aerosol output during inspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/13,33\">",
"     13,33",
"    </a>",
"    ]. However, these increased flows can result in greater drug loss during exhalation.",
"   </p>",
"   <p>",
"    The drug wastage of the open-vent jet nebulizer can be partially overcome by using a breath-enhanced system, because these nebulizers entrain gas only during inspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/13,21\">",
"     13,21",
"    </a>",
"    ]. Use of a breath-enhanced nebulizer may increase the delivered dose by as much as 20 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advantages of breath-enhanced, open-vent nebulizers include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/9,34,35\">",
"     9,34,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Production of smaller particles in aerosol",
"     </li>",
"     <li>",
"      Faster nebulization rates as compared with conventional nebulizers",
"     </li>",
"     <li>",
"      Increased aerosol delivery to the patient with less wastage",
"     </li>",
"     <li>",
"      Lower compressed airflow required",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The disadvantages of open-vent jet nebulizers are that they are dependent upon patient's inspiratory flow rate and tidal volume for optimum function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/21\">",
"     21",
"    </a>",
"    ], and they cost more than conventional nebulizers.",
"   </p>",
"   <p>",
"    These nebulizers have not been fully evaluated in infants and very young children, although they appear to be more efficient than the conventional nebulizers generally used in the management of this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Storage bag nebulizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some nebulizers incorporate a storage bag with a one-way valve in the mouthpiece connector. Aerosol is collected in the bag during the expiratory phase and delivered to the patient on the subsequent inhalation, reducing medication waste.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intermittent nebulizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older intermittent nebulizers use a thumb control that allows the patient to manually cease gas flow to the nebulizer during exhalation, which greatly decreases drug wastage. However, these systems require good hand-breath coordination and increase nebulization times up to fourfold [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/33\">",
"     33",
"    </a>",
"    ], making them unsuitable for most young children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Breath-actuated nebulizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breath-actuated nebulizers generate aerosols in coordination with inspiration and are capable of delivering higher drug doses, although with longer nebulization times [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/33,38\">",
"     33,38",
"    </a>",
"    ]. These nebulizers are activated by a breath-actuated diaphragm at inspiratory flow rates as low as 15",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    A study of children presenting to an emergency department with acute asthma suggests that the delivery of a single dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    using a breath-actuated nebulizer (AeroEclipse&reg;, Monaghan Medical) (",
"    <a class=\"graphic graphic_picture graphicRef56942 \" href=\"UTD.htm?2/45/2770\">",
"     figure 3",
"    </a>",
"    ) is more effective than a single dose or one hour of continuous albuterol administration using a conventional jet nebulizer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/39\">",
"     39",
"    </a>",
"    ]. Of note, children as young as six months of age were able to breath-actuate the nebulizer, although a few initially required manual activation for four to six breaths due to their high clinical respiratory scores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NEBULIZERS FOR SPECIFIC MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specially constructed small-volume nebulizers with closed scavenging systems were developed to prevent potentially toxic aerosolized medications from entering the general environment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/6\">",
"     6",
"    </a>",
"    ]. The Respirgard II for aerosolized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/54/37734?source=see_link\">",
"     pentamidine",
"    </a>",
"    , for example, is fitted with one-way valves and filters to minimize gross contamination of the environment.",
"   </p>",
"   <p>",
"    A separate device was developed to allow the safe delivery of aerosolized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     ribavirin",
"    </a>",
"    , which is potentially teratogenic. The Small-Particle Aerosol Generator (SPAG) was designed specifically to aerosolize ribavirin. It consists of a jet nebulizer and drying chamber that together reduce the MMAD to a mean of 1.3 micrometers, which optimizes drug delivery to distal airspaces. The SPAG is used with a scavenging system to minimize contamination of the ambient environment.",
"   </p>",
"   <p>",
"    Other medication solutions for nebulization, including DNase I (dornase alpha, Pulmozyme&reg;; Hudson, Marquest, and Pari LC nebulizers),",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/39/22129?source=see_link\">",
"     tobramycin",
"    </a>",
"    (TOBI&reg;; Pari LC Plus nebulizer), and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1430?source=see_link\">",
"     aztreonam",
"    </a>",
"    (Cayston&reg;; Altera nebulizer) should only be delivered using nebulizers specifically approved by the drug manufacturer for use with these agents. Results may not be the same if other nebulizers are used instead of those studied with the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1352583\">",
"    <span class=\"h1\">",
"     CONTINUOUS NEBULIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta agonists are commonly administered as a continuously nebulized aerosol in children with severe asthma exacerbations (",
"    <a class=\"graphic graphic_table graphicRef68683 \" href=\"UTD.htm?4/34/4654\">",
"     table 3",
"    </a>",
"    ). Multiple studies have demonstrated the efficacy and safety of this technique, even when high doses (eg, 20",
"    <span class=\"nowrap\">",
"     mg/hr",
"    </span>",
"    of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    ) are used [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/40-45\">",
"     40-45",
"    </a>",
"    ]. In addition, drug delivery over time by continuous nebulization appears similar to that with frequent intermittent nebulization, but potentially with a reduction in medical personnel time and costs of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/46\">",
"     46",
"    </a>",
"    ]. However, studies of continuous nebulization versus intermittent nebulization are uncontrolled and lack objective data (ie, pulmonary function) to support the use of one method over the other.",
"   </p>",
"   <p>",
"    Continuous nebulization requires a special delivery system to avoid the need for refilling the standard, small volume nebulizer every 10 to 15 minutes. Several strategies have been employed for administering continuously nebulized aerosols:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small volume nebulizer may be fitted with an intravenous infusion pump that drips premixed bronchodilator solution into the nebulizer chamber (",
"      <a class=\"graphic graphic_figure graphicRef73109 \" href=\"UTD.htm?1/62/2016\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef86236 \" href=\"UTD.htm?17/5/17492\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/12,43,47\">",
"       12,43,47",
"      </a>",
"      ]. This is the preferred method at the author's institution (due to cost and desire to limit inventories and devices).",
"     </li>",
"     <li>",
"      A large volume nebulizer (eg, the HEART&trade; nebulizer) that can generate around 30",
"      <span class=\"nowrap\">",
"       mL/hr",
"      </span>",
"      of aerosol can be used (",
"      <a class=\"graphic graphic_picture graphicRef83685 \" href=\"UTD.htm?22/19/22847\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Continuous aerosolized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    also can be delivered effectively using a mixture of helium and oxygen (Heliox), although a higher driving flow rate (11",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=see_link\">",
"     \"Physiology and clinical use of heliox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     USING A JET NEBULIZER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and parents should receive explicit instruction on the appropriate use of jet nebulizers (",
"    <a class=\"graphic graphic_table graphicRef71696 \" href=\"UTD.htm?14/37/14939\">",
"     table 4",
"    </a>",
"    ). Several technical factors complicate the use of these devices in the home. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31014?source=see_link\">",
"     \"Delivery of inhaled medication in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Compressors for home use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of jet nebulizers in the home requires a compressor to generate the driving airflow. However, commercial compressors vary widely in the flow rates they generate, and different",
"    <span class=\"nowrap\">",
"     nebulizer/compressor",
"    </span>",
"    combinations may have marked differences in how efficiently they generate respirable output [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/12,20,48\">",
"     12,20,48",
"    </a>",
"    ]. Compressors generating flow rates that are too low to drive a given nebulizer will result in negligible respirable output and ineffective therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only those",
"    <span class=\"nowrap\">",
"     nebulizer/compressor",
"    </span>",
"    combinations that are known to deliver at least 50 percent of each ordered drug as respirable particles within 10 minutes should be prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/12,48\">",
"     12,48",
"    </a>",
"    ]. The standard compressor used in many studies of nebulizer performance in the United States is the DeVilbiss Pulmoaide compressor, which is specified for use when administering aerosolized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/39/22129?source=see_link\">",
"     tobramycin",
"    </a>",
"    (TOBI) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/21,49,50\">",
"     21,49,50",
"    </a>",
"    ]. Unfortunately, there are no minimal standards for",
"    <span class=\"nowrap\">",
"     nebulizer/compressor",
"    </span>",
"    performance in North America, although such standards do exist in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. Most compressors for home use have a five year warranty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Infection control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeated use of disposable nebulizers may lead to bacterial contamination and nosocomial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. Home nebulizers meant for longer term use also are frequently contaminated with bacteria, but standardized guidelines for disinfecting home nebulizers are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/55\">",
"     55",
"    </a>",
"    ]. At a minimum, home nebulizers should be cleaned by rinsing and air-dried between uses to prevent clogging of the Venturi, and to reduce microbial contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/12\">",
"     12",
"    </a>",
"    ]. It is also recommended that nebulizers be disinfected by soaking one to two times per week in an",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/39/42610?source=see_link\">",
"     acetic acid",
"    </a>",
"    solution for 30 minutes (one part distilled white vinegar to three parts warm water) or in a commercial quaternary ammonium compound for 10 minutes, although even these measures may not provide adequate sterilization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The final rinse should be with tap water. Home nebulizers and the compressor filter should be replaced every six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Allergen control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reservoirs of home nebulizers also may be contaminated by indoor allergens. In one study, the reservoirs of 5 of 17 nebulizers collected from the homes of children with asthma were contaminated by at least one antigen (cockroach, cat, dog, mouse) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/57\">",
"     57",
"    </a>",
"    ]. Proper cleaning of nebulizers, as described above, and storage of nebulizers in plastic bags may prevent contamination with allergens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1352407\">",
"    <span class=\"h2\">",
"     Performance deterioration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some potential for performance deterioration of nebulizers used at home repeatedly over time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], although this risk appears minimal if these units are properly maintained and rinsed between uses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30376/abstract/60\">",
"     60",
"    </a>",
"    ]. The replacement time interval is based upon the manufacturer&rsquo;s recommendation for each specific nebulizer but should not exceed six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"       \"Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=see_link\">",
"       \"Patient information: Asthma treatment in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4042862\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nebulizers are used to provide aerosol therapy to patients too ill or too young to use hand-held devices and in situations where large drug doses and combination therapy are necessary. These devices also are required for some medications available only in aerosol form. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three basic types of nebulizers: jet nebulizers, ultrasonic nebulizers, and vibrating mesh nebulizers (",
"      <a class=\"graphic graphic_table graphicRef64982 \" href=\"UTD.htm?43/38/44652\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Basic types of nebulizers'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Jet nebulizers (",
"      <a class=\"graphic graphic_figure graphicRef75397 \" href=\"UTD.htm?1/7/1137\">",
"       figure 1",
"      </a>",
"      ) are the most commonly used form of nebulizer due to their lower cost and comparable clinical efficacy in many situations.",
"     </li>",
"     <li>",
"      Ultrasonic nebulizers can nebulize large volumes of liquid more quickly and, unlike jet nebulizers, do not require a source of driving gas. However, particle sizes may be larger with these devices, and the high-density aerosols generated are associated with bronchospasm and increased airway resistance in some patients. In addition, ultrasonic nebulizers do not nebulize suspensions efficiently and potentially could break down complex molecules, reducing their effect.",
"     </li>",
"     <li>",
"      Vibrating mesh nebulizers (",
"      <a class=\"graphic graphic_figure graphicRef69736 \" href=\"UTD.htm?37/3/37951\">",
"       figure 2",
"      </a>",
"      ) are more efficient than other conventional nebulizers, but are also more costly and must be disassembled and cleaned after each use to prevent clogging of the pores within the membrane. They are generally selected for use with expensive medications to minimize drug waste.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factors that can affect jet nebulizer performance include nebulization time, chamber design, driving gas used, dead volume, and physical properties of the solution or suspension. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Factors affecting jet nebulizer performance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enhancements to the design of jet nebulizers have improved performance and reduced aerosol waste during the exhalation phase (",
"      <a class=\"graphic graphic_picture graphicRef56942 \" href=\"UTD.htm?2/45/2770\">",
"       figure 3",
"      </a>",
"      ). These types include breath-enhanced open-vent, storage bag, intermittent, and breath-actuated nebulizers. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Enhanced jet nebulizer designs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specially constructed small-volume nebulizers with closed scavenging systems were developed to prevent potentially toxic aerosolized medications from entering the general environment. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Nebulizers for specific medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Beta agonists are commonly administered as a continuously nebulized aerosol in children with severe asthma exacerbations in emergency departments and inpatient units. Continuous nebulization requires a special delivery system to avoid the need for refilling the standard, small volume nebulizer every 10 to 15 minutes (",
"      <a class=\"graphic graphic_figure graphicRef73109 \" href=\"UTD.htm?1/62/2016\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef86236 \" href=\"UTD.htm?17/5/17492\">",
"       figure 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1352583\">",
"       'Continuous nebulization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients and parents should receive explicit instruction on the appropriate use of jet nebulizers (",
"      <a class=\"graphic graphic_table graphicRef71696 \" href=\"UTD.htm?14/37/14939\">",
"       table 4",
"      </a>",
"      ). Several technical factors complicate the use of these devices in the home, including the ability of the compress to deliver sufficient flow rate and infection and allergen control. Drug delivery can be improved with several simple measures, such as increasing the fill volume to at least 4 mL and warming the solution. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Using a jet nebulizer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/1\">",
"      Coates AL, Ho SL. Drug administration by jet nebulization. Pediatr Pulmonol 1998; 26:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/2\">",
"      O'Donohue WJ Jr. Guidelines for the use of nebulizers in the home and at domiciliary sites. Report of a consensus conference. National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. Chest 1996; 109:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/3\">",
"      Dolovich MA, MacIntyre NR, Anderson PJ, et al. Consensus statement: aerosols and delivery devices. American Association for Respiratory Care. Respir Care 2000; 45:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/4\">",
"      Hardy JG, Newman SP, Knoch M. Lung deposition from four nebulizers. Respir Med 1993; 87:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/5\">",
"      Hess D, Fisher D, Williams P, et al. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996; 110:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/6\">",
"      Hess DR. Nebulizers: principles and performance. Respir Care 2000; 45:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/7\">",
"      Clay MM, Pavia D, Newman SP, Clarke SW. Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 1983; 38:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/8\">",
"      Kendrick AH, Smith EC. Optimizing nebulization practice. Respir Med 1996; 90:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/9\">",
"      O'Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997; 52 Suppl 2:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/10\">",
"      Bucholski A, Keller M, Balcke A, et al. In vitro performance of eFlowTM, an electronic inhaler for administration of a novel aztreonam formulation to CF patients. Pediatr Pulmonol Suppl 2003; 25:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/11\">",
"      Lass JS, Sant A, Knoch M. New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Expert Opin Drug Deliv 2006; 3:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/12\">",
"      Rubin BK, Fink JB. Aerosol therapy for children. Respir Care Clin N Am 2001; 7:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/13\">",
"      O'Callaghan C, Barry PW. Asthma drug delivery devices for children. BMJ 2000; 320:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/14\">",
"      O'Callaghan C, Clark AR, Milner AD. Why nebulise for more than five minutes? Arch Dis Child 1989; 64:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/15\">",
"      Malone RA, Hollie MC, Glynn-Barnhart A, Nelson HS. Optimal duration of nebulized albuterol therapy. Chest 1993; 104:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/16\">",
"      Dennis JH, Hendrick DJ. Design characteristics for drug nebulizers. J Med Eng Technol 1992; 16:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/17\">",
"      Wildhaber JH, Dore ND, Wilson JM, et al. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999; 135:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/18\">",
"      Clay MM, Pavia D, Newman SP, et al. Assessment of jet nebulisers for lung aerosol therapy. Lancet 1983; 2:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/19\">",
"      Coates AL, MacNeish CF, Meisner D, et al. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 1997; 111:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/20\">",
"      Reisner C, Katial RK, Bartelson BB, et al. Characterization of aerosol output from various nebulizer/compressor combinations. Ann Allergy Asthma Immunol 2001; 86:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/21\">",
"      Coates AL, MacNeish CF, Lands LC, et al. A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers. Chest 1998; 113:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/22\">",
"      Hess DR, Acosta FL, Ritz RH, et al. The effect of heliox on nebulizer function using a beta-agonist bronchodilator. Chest 1999; 115:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/23\">",
"      Kress JP, Noth I, Gehlbach BK, et al. The utility of albuterol nebulized with heliox during acute asthma exacerbations. Am J Respir Crit Care Med 2002; 165:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/24\">",
"      Henderson SO, Acharya P, Kilaghbian T, et al. Use of heliox-driven nebulizer therapy in the treatment of acute asthma. Ann Emerg Med 1999; 33:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/25\">",
"      Anderson M, Svartengren M, Philioson K, et al. Deposition in man of particles suspended in air or in helium-oxygen mixture at different flow rates. J Aerosol Med 1990; 3:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/26\">",
"      Anderson M, Svartengren M, Bylin G, et al. Deposition in asthmatics of particles inhaled in air or in helium-oxygen. Am Rev Respir Dis 1993; 147:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/27\">",
"      Habib DM, Garner SS, Brandeburg S. Effect of helium-oxygen on delivery of albuterol in a pediatric, volume-cycled, ventilated lung model. Pharmacotherapy 1999; 19:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/28\">",
"      Svartengren M, Anderson M, Philipson K, Camner P. Human lung deposition of particles suspended in air or in helium/oxygen mixture. Exp Lung Res 1989; 15:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/29\">",
"      Bigham MT, Jacobs BR, Monaco MA, et al. Helium/oxygen-driven albuterol nebulization in the management of children with status asthmaticus: a randomized, placebo-controlled trial. Pediatr Crit Care Med 2010; 11:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/30\">",
"      Ho SL, Coates AL. Effect of dead volume on the efficiency and the cost to deliver medications in cystic fibrosis with four disposable nebulizers. Can Respir J 1999; 6:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/31\">",
"      Schueepp KG, Devadason SG, Roller C, et al. Aerosol delivery of nebulised budesonide in young children with asthma. Respir Med 2009; 103:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/32\">",
"      Kundoor V, Dalby RN. Assessment of facial and ocular deposition of nebulized aerosol using a color-based method. Drug Dev Ind Pharm 2010; 36:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/33\">",
"      Fink JB. Aerosol device selection: evidence to practice. Respir Care 2000; 45:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/34\">",
"      Barry PW, O'Callaghan C. An in vitro analysis of the output of budesonide from different nebulizers. J Allergy Clin Immunol 1999; 104:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/35\">",
"      Barry PW, O'Callaghan C. An in vitro analysis of the output of salbutamol from different nebulizers. Eur Respir J 1999; 13:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/36\">",
"      Devadason SG, Everard ML, Linto JM, Le Sou&euml;f PN. Comparison of drug delivery from conventional versus \"Venturi\" nebulizers. Eur Respir J 1997; 10:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/37\">",
"      Wildhaber JH, Devadason SG, Eber E, et al. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 1996; 51:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/38\">",
"      Nikander K, Agertoft L, Pedersen S. Breath-synchronized nebulization diminishes the impact of patient-device interfaces (face mask or mouthpiece) on the inhaled mass of nebulized budesonide. J Asthma 2000; 37:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/39\">",
"      Sabato K, Ward P, Hawk W, et al. Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department. Respir Care 2011; 56:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/40\">",
"      Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993; 21:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/41\">",
"      Katz RW, Kelly HW, Crowley MR, et al. Safety of continuous nebulized albuterol for bronchospasm in infants and children. Pediatrics 1993; 92:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/42\">",
"      Moler FW, Johnson CE, Van Laanen C, et al. Continuous versus intermittent nebulized terbutaline: plasma levels and effects. Am J Respir Crit Care Med 1995; 151:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/43\">",
"      Moler FW, Hurwitz ME, Custer JR. Improvement in clinical asthma score and PaCO2 in children with severe asthma treated with continuously nebulized terbutaline. J Allergy Clin Immunol 1988; 81:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/44\">",
"      Portnoy J, Nadel G, Amado M, Willsie-Ediger S. Continuous nebulization for status asthmaticus. Ann Allergy 1992; 69:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/45\">",
"      Portnoy J, Aggarwal J. Continuous terbutaline nebulization for the treatment of severe exacerbations of asthma in children. Ann Allergy 1988; 60:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/46\">",
"      McPeck M, Tandon R, Hughes K, Smaldone GC. Aerosol delivery during continuous nebulization. Chest 1997; 111:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/47\">",
"      Voss KR, Willsie-Ediger SK, Pyszczynski DR, Nelson KA. Description of a delivery method for continuously aerosolized albuterol in status asthmaticus. J Asthma 1990; 27:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/48\">",
"      Berg EB, Picard RJ. In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns. Respir Care 2009; 54:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/49\">",
"      Loffert DT, Ikle D, Nelson HS. A comparison of commercial jet nebulizers. Chest 1994; 106:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/50\">",
"      Standaert TA, Vandevanter D, Ramsey BW, et al. The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer. J Aerosol Med 2000; 13:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/51\">",
"      Jakobsson BM, Onnered AB, Hjelte L, Nystr&ouml;m B. Low bacterial contamination of nebulizers in home treatment of cystic fibrosis patients. J Hosp Infect 1997; 36:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/52\">",
"      Hutchinson GR, Parker S, Pryor JA, et al. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol 1996; 34:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/53\">",
"      Wexler MR, Rhame FS, Blumenthal MN, et al. Transmission of gram-negative bacilli to asthmatic children via home nebulizers. Ann Allergy 1991; 66:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/54\">",
"      Guideline for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention. Respir Care 1994; 39:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/55\">",
"      Rosenfeld M, Emerson J, Astley S, et al. Home nebulizer use among patients with cystic fibrosis. J Pediatr 1998; 132:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/56\">",
"      Chatburn RL, Kallstrom TJ, Bajaksouzian SA. A comparison of acetic acid with a quaternary ammonium compound for disinfection of hand-held nebulizers. Respir Care 1988; 33:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/57\">",
"      Bollinger ME, Butz A, Mudd K, Hamilton RG. Contamination of nebulizers with environmental allergens. Ann Allergy Asthma Immunol 2005; 95:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/58\">",
"      Alvine GF, Rodgers P, Fitzsimmons KM, Ahrens RC. Disposable jet nebulizers. How reliable are they? Chest 1992; 101:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/59\">",
"      Coates AL, Canny G, Zinman R, et al. The effects of chronic airflow limitation, increased dead space, and the pattern of ventilation on gas exchange during maximal exercise in advanced cystic fibrosis. Am Rev Respir Dis 1988; 138:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30376/abstract/60\">",
"      Standaert TA, Morlin GL, Williams-Warren J, et al. Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest 1998; 114:577.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5736 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30376=[""].join("\n");
var outline_f29_42_30376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4042862\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BASIC TYPES OF NEBULIZERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Jet nebulizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ultrasonic nebulizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H383507745\">",
"      Vibrating mesh nebulizers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FACTORS AFFECTING JET NEBULIZER PERFORMANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ENHANCED JET NEBULIZER DESIGNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Breath-enhanced open-vent nebulizer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Storage bag nebulizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intermittent nebulizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Breath-actuated nebulizers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NEBULIZERS FOR SPECIFIC MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1352583\">",
"      CONTINUOUS NEBULIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      USING A JET NEBULIZER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Compressors for home use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Infection control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Allergen control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1352407\">",
"      Performance deterioration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4042862\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5736\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5736|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/7/1137\" title=\"figure 1\">",
"      Jet nebulizer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/3/37951\" title=\"figure 2\">",
"      Mesh nebulizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/62/2016\" title=\"figure 4\">",
"      Ventilator delivery B agonist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/5/17492\" title=\"figure 5\">",
"      Continuous bronchodilator nebulization in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5736|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/45/2770\" title=\"figure 3\">",
"      Nebulizers new designs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/19/22847\" title=\"picture 1\">",
"      Large volume nebulizer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5736|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/38/44652\" title=\"table 1\">",
"      Advantages and disadvantages of different types of nebulizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/24/33163\" title=\"table 2\">",
"      Nebulizer performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/34/4654\" title=\"table 3\">",
"      Doses of beta agonists for asthma exacerbations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/37/14939\" title=\"table 4\">",
"      Nebulizer technique",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31014?source=related_link\">",
"      Delivery of inhaled medication in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=related_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=related_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=related_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=related_link\">",
"      Physiology and clinical use of heliox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=related_link\">",
"      The use of inhaler devices in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_42_30377="Urothelial papilloma";
var content_f29_42_30377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Urothelial papilloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A-D: Most papillomas have a simple non-branching arrangement, slender fibrovascular stalks, with a predominantly exophytic pattern. Papillary fronds are lined by normal appearing urothelium (20x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30377=[""].join("\n");
var outline_f29_42_30377=null;
var title_f29_42_30378="Management of late complications of head and neck cancer and its treatment";
var content_f29_42_30378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of late complications of head and neck cancer and its treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/42/30378/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/42/30378/contributors\">",
"     Thomas Galloway, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/42/30378/contributors\">",
"     Robert J Amdur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/42/30378/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/42/30378/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/42/30378/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/42/30378/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/42/30378/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/42/30378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/42/30378/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/42/30378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxicity from cancer therapy is classified as acute or late based upon when it develops relative to treatment. Acute toxicity develops during or shortly after the completion of treatment and is usually temporary. Late toxicity presents months to years after the completion of treatment and is often permanent. The term complication is used for a treatment toxicity that causes an important medical problem.",
"   </p>",
"   <p>",
"    This topic will review the late complications of treatment for head and neck cancer. The care of patients with head and neck cancer during initial therapy, both to treat acute toxicity and to prevent late complications, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822348\">",
"    <span class=\"h1\">",
"     SALIVARY GLAND DAMAGE AND XEROSTOMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common long-term complication of radiation therapy (RT) and chemoradiotherapy for head and neck cancer is xerostomia, which is the result of damage to the salivary glands.",
"   </p>",
"   <p>",
"    The magnitude of this damage is dose dependent. Parotid dysfunction can be detectable at 10 to 15 Gy mean dose, and administration of approximately 40 to 50 Gy mean dose to a parotid gland typically causes &gt;75 percent reduction in function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although xerostomia often improves with time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/2\">",
"     2",
"    </a>",
"    ], it is a long lasting and frequently permanent problem that adversely impacts quality of life. The management of patients with established xerostomia includes multiple maneuvers to provide alternative wetting agents and maximize residual function of the salivary glands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H707301954\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of contemporary conformal RT techniques to minimize exposure of the salivary glands to radiation is the most important factor in the prevention of permanent salivary gland damage.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     Amifostine",
"    </a>",
"    and submandibular salivary gland transfer may have roles in appropriately selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H722454151#H722454151\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058958030\">",
"    <span class=\"h2\">",
"     Lifestyle modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some degree of xerostomia is expected in almost all patients who receive head and neck RT. Significant beneficial interventions can be achieved by the patient independent of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    physicians. Dietary change from dry, tough food to moist, softer food can greatly improve nutritional status and quality of life. Use of a room humidifier in the bedroom can also provide some benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822356\">",
"    <span class=\"h2\">",
"     Saliva substitutes and mucosal lubricants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercially available salivary substitutes or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/59/37811?source=see_link\">",
"     artificial saliva",
"    </a>",
"    (oral rinses containing hyetellose, hyprolose, or carmellose) relieve the discomfort of xerostomia by wetting the oral mucosa.",
"   </p>",
"   <p>",
"    Although these agents may provide temporary relief, many patients need frequent sips of water to remain comfortable. In addition to being inconvenient, this can lead to secondary problems such as nocturia from late night fluid intake in men with prostatic hypertrophy and in men and women with small bladder capacity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=see_link\">",
"     \"Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822376\">",
"    <span class=\"h2\">",
"     Stimulation of existing salivary flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various gustatory, tactile, or pharmacologic agents are used to stimulate the flow of saliva from residual salivary gland tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822384\">",
"    <span class=\"h3\">",
"     Nonpharmacologic stimuli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gustatory stimuli such as acidic or bitter substances are most effective at stimulating salivary flow [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/4\">",
"     4",
"    </a>",
"    ]. Sweet substances such as sugar-free hard candy also stimulate the flow of saliva but to a lesser extent. Chewing sugarless gum can provide both gustatory and tactile stimuli to salivary flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822392\">",
"    <span class=\"h3\">",
"     Pharmacologic stimuli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parasympathomimetic agents that target the muscarinic (M3) receptor are used to stimulate saliva production by residual glandular tissue.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     Pilocarpine",
"    </a>",
"    has been the most extensively investigated, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    may offer advantages in terms of an improved side effects profile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822400\">",
"    <span class=\"h4\">",
"     Pilocarpine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of the literature identified nine randomized trials that studied",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    in the postradiation setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/5\">",
"     5",
"    </a>",
"    ]. The review concluded that approximately 50 percent of patients with xerostomia benefit from oral pilocarpine following RT. Continuous treatment with doses greater than 2.5 mg three times per day is required for optimal response, with some patients needing up to 12 weeks to experience benefit. Lifelong therapy is required.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     Pilocarpine",
"    </a>",
"    causes frequent side effects, most of which are the result of generalized parasympathomimetic stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/6\">",
"     6",
"    </a>",
"    ]. These include sweating, headaches, tachycardia, hypertension, flushing, and increased bowel and bladder motility. Pilocarpine should be avoided in patients with uncontrolled asthma, acute angle glaucoma, or known hypersensitivity to pilocarpine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822407\">",
"    <span class=\"h4\">",
"     Cevimeline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12932?source=see_link\">",
"     Cevimeline",
"    </a>",
"    is an acetylcholine analog that has a high affinity for the M3 muscarinic receptors of salivary gland, but a low affinity for the M2 muscarinic receptors of heart and lung tissue.",
"   </p>",
"   <p>",
"    In two identically designed trials, a total of 570 patients who had received at least 40 Gy of radiation to fields that included the major salivary glands were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    (30 mg three times daily) or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/7\">",
"     7",
"    </a>",
"    ]. Cevimeline could be increased to 45 mg per dose starting at week six. Cevimeline-treated subjects had significantly greater increases in unstimulated salivary flow, but no difference in the stimulated salivary flow. There was no significant difference in the subjective evaluation of oral dryness.",
"   </p>",
"   <p>",
"    Adverse effects are frequent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12932?source=see_link\">",
"     cevimeline",
"    </a>",
"    , even though its side effect profile may be more favorable than that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    . In an open-label study of long-term cevimeline use (45 mg three times daily for 52 weeks) in 255 adult patients with postirradiation xerostomia, 175 (69 percent) experienced an adverse effect, mostly mild to moderate in severity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/8\">",
"     8",
"    </a>",
"    ]. The most frequent effects were sweating (48 percent), dyspepsia (9 percent), nausea (8 percent) and diarrhea (6 percent). At the final visit, subjective improvement of dry mouth was reported by 59 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822414\">",
"    <span class=\"h3\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small, randomized trials suggest that acupuncture provides meaningful palliation for patients with xerostomia who have at least some residual salivary gland function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Additional clinical trials are needed to validate this approach and to define the mechanism of action and duration of benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=see_link&amp;anchor=H27#H27\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Acupuncture and related therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058958037\">",
"    <span class=\"h3\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pilot study evaluated the salivary effects of hyperbaric oxygen in a group of 80 patients, 45 of whom had hyposalivation. Patient self-assessment of xerostomia, unstimulated, and stimulated whole saliva flow rate all increased after 30 sessions of hyperbaric oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/12\">",
"     12",
"    </a>",
"    ]. These results suggest that hyperbaric oxygen may have a beneficial effect on xerostomia, but must be confirmed on a larger scale before such therapy can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822433\">",
"    <span class=\"h1\">",
"     DENTAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental status has a significant effect on posttreatment quality of life among patients with head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Patients with head and neck cancer often have poor preexisting dentition and dental health. Poor dentition increases the risk of late complications, including osteoradionecrosis and infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H722455156#H722455156\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Dental issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reduced quantity and altered composition of saliva is known to increase the risk of dental caries. Thus, patients should have pretreatment dental evaluation to include the initiation of fluoride treatments, and other oral and dental hygiene which should be continued on a lifelong basis. Long-term follow-up by an experienced dentist is necessary.",
"   </p>",
"   <p>",
"    Patients who require dental extractions in a previously irradiated area of mandible or maxilla are at risk to develop osteoradionecrosis. (See",
"    <a class=\"local\" href=\"#H3822453\">",
"     'Osteoradionecrosis and soft tissue necrosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822453\">",
"    <span class=\"h1\">",
"     OSTEORADIONECROSIS AND SOFT TISSUE NECROSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822476\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoradionecrosis is defined as exposed, irradiated bone in the absence of recurrent or residual tumor. Osteoradionecrosis is a complication of radiotherapy due to vascular obliteration and decreased vascular supply of the irradiated tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/15\">",
"     15",
"    </a>",
"    ]. This leads to hypovascular areas with associated tissue hypoxia. Osteoradionecrosis is commonly precipitated by an injury (surgery, dental extractions, poor dentition, infection) to hypoxic bone tissue.",
"   </p>",
"   <p>",
"    Symptoms of osteoradionecrosis can include pain, bad breath, dysgeusia, dysesthesia or anesthesia, trismus, difficulty with chewing and swallowing, speech difficulties, fistula formation, pathologic fracture, and infection. The radiologic interpretation of osteomyelitis of the mandible in a patient who has been treated with RT for head and neck cancer should be interpreted as osteomyelitis superimposed on osteoradionecrosis until proven otherwise.",
"   </p>",
"   <p>",
"    In some cases, osteoradionecrosis is manifested by asymptomatic exposure of a small area of bone that remains stable for months to years and heals with conservative management. In other cases, osteoradionecrosis may gradually progress and be associated with skin fistulas or infections. Severe necrosis may require surgical intervention and reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time to onset of osteoradionecrosis is quite variable. In some cases, it may be diagnosed shortly after completion of RT, while in other patients it may not be diagnosed for years after the original cancer treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mandible is the most frequently affected bone, because in the majority of patients treated for head and neck cancer, a large part of the mandible is exposed to high doses of radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/18\">",
"     18",
"    </a>",
"    ]. Maxillary osteoradionecrosis is rare, and seen most often in the setting of irradiation for nasopharyngeal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822484\">",
"    <span class=\"h2\">",
"     Epidemiology and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that affect the risk of developing osteoradionecrosis include tumor location, radiation technique and dose, and acute and chronic trauma to the mandible",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maxilla.",
"   </p>",
"   <p>",
"    RT to oral cavity targets generally administers higher doses of radiation to larger volumes of the mandible than treatment of targets in the pharynx and larynx. As a consequence, osteoradionecrosis is most common in patients treated for tumors of the oral cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of the literature that included 31 studies and over 4200 patients found that the incidence of osteoradionecrosis was similar regardless of treatment technique, ranging from 5 to 7 percent with conventional RT, IMRT, chemoradiotherapy (generally not using IMRT), or brachytherapy (with or without and external beam component) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/16\">",
"     16",
"    </a>",
"    ]. The largest North American series of fast neutron therapy for targets above the clavicles observed a relatively low rate of osteoradionecrosis of the mandible or facial bones (crude incidence rate of 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/20\">",
"     20",
"    </a>",
"    ]. The crude incidence of osteoradionecrosis with reirradiation is only slightly higher than that seen during the initial course of RT likely secondary to small expansions in the reirradiation setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the impact of radiotherapy technique should not be minimized. When using IMRT, failure to limit &ldquo;hot-spots&rdquo; in the mandible can deposit excess dose and lead to osteoradionecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. When using brachytherapy, differences in the relative contribution of the external beam and brachytherapy components of treatment can cause widely different crude incidence rates of osteoradionecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/25\">",
"     25",
"    </a>",
"    ]. Finally, these comprehensive analyses include relatively few patients treated with IMRT and concurrent chemotherapy, the current standard of care for advanced head and neck cancer.",
"   </p>",
"   <p>",
"    Unnecessary trauma to the irradiated",
"    <span class=\"nowrap\">",
"     mandible/maxilla",
"    </span>",
"    is to be avoided. This is at times difficult; a comprehensive review of dental disease in patients undergoing cancer therapy found that postradiotherapy patients had the highest incidence of decayed, missing, and filled teeth of all cancer patients surveyed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/26\">",
"     26",
"    </a>",
"    ]. The association of osteoradionecrosis with dental factors has led to the recommendations for dental management during and after the initial treatment of patients with head and neck cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H722455156#H722455156\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Dental issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822503\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of osteoradionecrosis is complex. For mild cases of osteoradionecrosis, conservative debridement and antibiotics is usually successful [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/27\">",
"     27",
"    </a>",
"    ]. However, when bone and soft tissue necrosis are extensive, resection of the mandible with immediate microvascular reconstruction may provide better results [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Recurrent cancer must always be considered in the differential diagnosis of exposed mandible or maxilla especially if the exposure is in the same general anatomic area as the previously treated tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H975122994\">",
"    <span class=\"h3\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbaric oxygen is used at many centers to prevent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treat osteoradionecrosis. Hyperbaric oxygen is thought to act by stimulating monocyte and fibroblast function, thereby increasing vascular density and improving circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the available data on the efficacy of hyperbaric oxygen are limited and conflicting, and comprehensive randomized trials are needed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of osteoradionecrosis refers to the situation where trauma to the mandible (eg, dental repair) is planned.",
"      <br/>",
"      <br/>",
"      Prevention was tested in a randomized trial of irradiated patients needing teeth extractions who were randomized to perioperative penicillin versus perioperative penicillin plus hyperbaric oxygen therapy. There was a statistically significant decrease in the incidence of osteoradionecrosis in patients treated with hyperbaric oxygen (30 versus 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/32\">",
"       32",
"      </a>",
"      ]. Other retrospective studies have confirmed the low rate of osteoradionecrosis with postirradiation extractions using this technique [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/33\">",
"       33",
"      </a>",
"      ]. By contrast, a single institution analysis of pre- and postradiation extractions reported a low rate of osteoradionecrosis (2 percent) despite the use of hyperbaric oxygen in only 4 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment of osteoradionecrosis refers to the situation where certain clinical symptoms (pain, dysesthesia in the distribution of the inferior alveolar nerve, areas of bone exposure, trismus, fistula), radiographic findings (increased density, periosteal thickening, diffuse radiolucency, mottled areas of osteoporosis, sclerosis sequestration), or physical examination findings (exposed bone) consistent with osteoradionecrosis are present.",
"      <br/>",
"      <br/>",
"      A randomized trial of the efficacy of hyperbaric oxygen in cases of overt osteoradionecrosis was closed prematurely secondary to a trend suggesting that hyperbaric oxygen was associated with worse outcomes than placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/35\">",
"       35",
"      </a>",
"      ]. It is unclear why the placebo arm of this trial performed much better than expected (10 percent recovery expected, 32 percent recovery recorded), although there were some imbalances in the randomization of the two treatment arms. By contrast, a retrospective study using a questionnaire administered to patients after completion of hyperbaric therapy reported that 75 percent of patients noted an improvement in their principal presenting symptom [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyperbaric oxygen is time consuming (typically requiring 30 to 40 treatments [&ldquo;dives&rdquo;] delivered once or twice daily, generally for five days a week and thus lasting for either three to four or for six to eight weeks) and is expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/37\">",
"     37",
"    </a>",
"    ]. The most common side effect is reversible myopia.",
"   </p>",
"   <p>",
"    Although there are only conflicting data on the efficacy of hyperbaric oxygen, many dentists use it to treat or prevent osteoradionecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/38\">",
"     38",
"    </a>",
"    ]. Its use for the treatment or prevention of osteoradionecrosis is generally governed by institutional guidelines.",
"   </p>",
"   <p>",
"    Soft tissue necrosis, which is most common in instances of reirradiation, is generally managed according to similar principles as osteoradionecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H975123001\">",
"    <span class=\"h3\">",
"     Pentoxifylline and vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single institution phase II study using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    and vitamin E in patients with refractory osteoradionecrosis resulted in all 54 patients experiencing a complete recovery in a median of nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/39\">",
"     39",
"    </a>",
"    ]. This finding needs to be confirmed in a randomized trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17129?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and treatment of radiation-induced fibrosis\", section on 'Pentoxifylline plus tocopherol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822522\">",
"    <span class=\"h1\">",
"     SOFT TISSUE FIBROSIS IN THE NECK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both surgery and RT can cause significant injury to the soft tissues of the neck.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RT to the neck may result in immobility, manifested by stiffening of muscles",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pain, and in severe cases flexion contractures. Edema of the neck is common [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/40\">",
"       40",
"      </a>",
"      ]. In time, this edema may harden, leading to neck stiffness. In severe cases, in particular when accompanied by neck dissection, or in the case of reirradiation, neck and facial edema may be extremely severe and cosmetically significant.",
"     </li>",
"     <li>",
"      Surgery to the neck can also result in hardening of the tissues of the neck or face, which can cause facial, submental, or, rarely, cerebral edema due to venous and lymphatic compromise [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/40\">",
"       40",
"      </a>",
"      ]. This is generally worse with bilateral neck dissection, with neck dissections that sacrifice the jugular vein, or when neck dissection follows or precedes RT. Contractures or loss of normal range of motion of the neck can occur, especially if neck dissection is combined with RT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatments that have been reported to be useful for neck",
"    <span class=\"nowrap\">",
"     stiffness/soft",
"    </span>",
"    tissue fibrosis in the neck include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], massage",
"    <span class=\"nowrap\">",
"     therapy/physical",
"    </span>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/43\">",
"     43",
"    </a>",
"    ], and botulinum toxin injections, particularly in setting of neck muscle spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822529\">",
"    <span class=\"h1\">",
"     CAROTID ARTERY INJURY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822537\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic stroke can be a late complication of neck irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. In one report of 367 patients who were treated with RT for head or neck tumors before age 60, the relative risk (RR) of ischemic stroke compared to age- and sex-adjusted, population-based rates, was 5.6 (95 percent confidence interval [CI] 3.1 to 9.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/46\">",
"     46",
"    </a>",
"    ], and the 15-year cumulative risk of stroke was 12 percent (95% CI 6.5 to 21.4 percent).",
"   </p>",
"   <p>",
"    Multiple factors may contribute to this increased risk in patients with head and neck cancer, including carotid artery stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/48\">",
"     48",
"    </a>",
"    ] and increased deposition of plaque [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/49\">",
"     49",
"    </a>",
"    ], as well as other preexisting risk factors for cerebrovascular disease, particularly smoking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link\">",
"     \"Etiology and classification of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is currently no standard screening mechanism for survivors. Screening ultrasound within the first year since completion of radiotherapy, followed by repeat ultrasounds every two to three years demonstrated &gt;50 percent occlusion in 21 percent of necks receiving 40 to 50 Gy. However, none of the patients suffered a stroke, and it is unclear what percentage of patients had stenosis prior to the initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822557\">",
"    <span class=\"h2\">",
"     Carotid artery rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid artery rupture (sometimes called \"carotid blowout syndrome\") is a medical emergency. Mortality is high, and emergency surgery is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/51\">",
"     51",
"    </a>",
"    ]. Endovascular stenting may have a role in managing patients with impending carotid artery rupture, in preference to surgical ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rupture of the carotid artery is most common in the setting of a surgically exposed carotid artery with limited residual normal tissue to cover it, recurrent tumor, infection, or severe radiation damage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/53\">",
"     53",
"    </a>",
"    ]. Carotid blowout syndrome usually occurs proximal to the carotid bifurcation and is commonly associated with soft tissue necrosis in the neck and mucocutaneous fistulas. In a case series and review of the literature that identified 140 patients with carotid artery events, 60 percent of patients had life-threatening hemorrhage that required emergency intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/52\">",
"     52",
"    </a>",
"    ]. A review of the incidence of carotid blowout in the setting of reirradiation suggested that the syndrome was more common in accelerated fractionation reirradiation techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822571\">",
"    <span class=\"h1\">",
"     TRISMUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inability to fully open the jaw has a variety of functional consequences, including impaired nutrition, speech, and oral hygiene. Trismus is a condition characterized by limited ability to open the jaw, which is generally caused by a combination of spasm, fibrosis, and contraction of the muscles responsible for movement at the temporomandibular joint [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/55\">",
"     55",
"    </a>",
"    ]. This is typically associated with radiation to these muscles, but surgery may also contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/56\">",
"     56",
"    </a>",
"    ]. Although there is no absolute interincisor distance that defines trismus, distances of 20 to 40 mm have been suggested as indicative of trismus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of trismus has varied widely in patients who received RT for head and neck cancer. A systematic review of the literature found that the mean prevalence of trismus was approximately 25 percent using older RT techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/55\">",
"     55",
"    </a>",
"    ]. However, newer techniques that minimize the dose of radiation to the muscles of mastication appear to significantly reduce the incidence of trismus. At least three reports using intensity modulated RT (IMRT) have found that the incidence of trismus was approximately 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Associated surgery can also significantly affect the incidence of trismus, both from the standpoint of primary site resection and surgical approaches such as mandibular split procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link&amp;anchor=H163948839#H163948839\">",
"     \"General principles of radiation therapy for head and neck cancer\", section on 'Three-dimensional conformal RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early treatment is important to prevent the development of severe, irreversible contractures. Although evidence is limited, the use of passive motion devices and splinting may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/61-63\">",
"     61-63",
"    </a>",
"    ], and these can be used in the early postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     Pentoxifylline",
"    </a>",
"    has been used to treat radiation-induced fibrosis; at least one preliminary study suggests that this may have a modest benefit in patients with trismus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/41\">",
"     41",
"    </a>",
"    ]. Injection of botulinum toxin directly into the masseter muscles may decrease pain and muscle spasm, but has not resulted in improvement of trismus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17129?source=see_link\">",
"     \"Clinical manifestations and treatment of radiation-induced fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H975123942\">",
"    <span class=\"h1\">",
"     DYSPHAGIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment-induced dysphagia can compromise the benefits of organ preservation. In addition to the effects of radiation, other causative factors including xerostomia, surgical disruption, and concurrent chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The locally destructive effects of the primary tumor prior to treatment can also contribute to dysphagia. The dose dependence of RT related dysfunction and its avoidance is complicated by need to deliver high doses radiation to eradicate tumor. When control of the tumor is not compromised, the radiation plan should be contoured to avoid the pharyngeal constrictor muscles.",
"   </p>",
"   <p>",
"    There are several methods by which to evaluate treatment related dysphagia: instrumental assessment (modified",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow, manometry, fiberoptic endoscopic evaluation of swallowing), subjective assessment (CTCAE grading), and patient reported quality of life forms (FACT H&amp;N, etc). The MD Anderson Dysphagia Index (MDADI) has been validated and is a useful tool for assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/67\">",
"     67",
"    </a>",
"    ]. It is not uncommon for different instruments to provide contradictory results for the same patient, making accurate comparisons and estimates of dysphagia incidence subject to some degree of uncertainty.",
"   </p>",
"   <p>",
"    A meta-analysis of three concurrent chemotherapy trials (RTOG 91-11, RTOG 97-03, RTOG 99-14) found that feeding tube use two or more years after RT (&gt;10 percent of evaluable patients) and pharyngeal dysfunction (27 percent of patients evaluable) were common. Older age, advanced T-stage,",
"    <span class=\"nowrap\">",
"     larynx/hypopharynx",
"    </span>",
"    primary, and posttreatment neck dissection were found to be predictive of severe late toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RT technique can have an important effect on the incidence and severity of dysphagia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective comparison of patients treated with either whole neck IMRT (entire elective lymphatic volume treated by an inverse planned IMRT technique) or split field IMRT (neck lymphatics below the thyroid notch treated by an anterior low neck field) demonstrated an increased rate of grade 3 dysphagia for patients treated with whole neck IMRT (95 versus 62.5 percent, p = 0.06). This was thought to be secondary to inadequate pharyngeal axis radiation avoidance in the whole neck IMRT group (mean dose: 55.2 versus 27.2 Gy, p&lt;0.001) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective review of 96 patients demonstrated a 37 percent rate of pharyngeal stricture following treatment. A mean radiation dose of greater than 50 Gy to the larynx and inferior pharyngeal constrictor was found to correlate with stricture and aspiration [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A proposed method to avoid radiotherapy dose related dysphagia is to enter the uninvolved pharyngeal constrictor muscles and larynx into the IMRT cost function as avoidance structures. This was evaluated in a prospective trial of oropharynx cancer patients that demonstrated that all measures of dysphagia worsened soon after therapy; however, the observer and patient reported scores recovered after time. After one year, only one patient was feeding tube dependent and three required a soft diet. Locoregional control was not affected by this technique (96 percent at three years) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A retrospective analysis suggested that prophylactic placement of a gastrostomy tube results in both a higher percentage of feeding-tube dependent patients at one year posttreatment (21 versus 0 percent, p&lt;0.001) and a higher rate of esophageal stricture (30 versus 6 percent), perhaps due to disuse of pharyngeal musculature during therapy. This needs to be confirmed prospectively. Placement of a feeding tube is at the discretion of the physician [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newer surgical techniques followed by postoperative RT have been postulated to cause less treatment-related dysphagia than combinations of RT and systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/72\">",
"     72",
"    </a>",
"    ]. However, this needs to be prospectively evaluated since much larger analyses that suggested that severe complications are much more common in patients managed with primary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Speech pathologists are a vital part of the head and neck cancer treatment team and should evaluate all patients receiving surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high dose radiotherapy that could potentially interfere with the ability to protect the airway or swallow. Neuromuscular electrical stimulation (NMSE) is a potentially promising improvement to traditional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822602\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal toxicity appears to be multifactorial in patients treated for head and neck cancer. Factors that may contribute include mucositis from RT or chemoradiotherapy, fibrosis in muscle, or changes due to alterations in bacterial flora or change in pH due to xerostomia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/74\">",
"     74",
"    </a>",
"    ]. Factors that appear to be particularly important in determining the frequency and severity of esophageal toxicity include the use of concurrent chemotherapy, duration of acute effects, dose of radiation, and primary tumors that are in close proximity to the esophageal verge (eg, laryngeal and hypopharyngeal primaries):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, the incidence of grade 3 or greater toxicity (able to swallow only liquids, dilatation required) was analyzed in 211 patients six months after treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/75\">",
"       75",
"      </a>",
"      ]. Toxicity was significantly more frequent in those treated with concurrent chemotherapy compared with RT alone (33 of 118 [30 percent] versus 7 of 93 [8 percent]). By contrast, multiple prospective studies evaluating concurrent chemoradiotherapy versus RT alone reported similar",
"      <span class=\"nowrap\">",
"       swallowing/esophageal",
"      </span>",
"      toxicity in both arms [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/66,76,77\">",
"       66,76,77",
"      </a>",
"      ]. The true influence of treatment intensification (ie, concurrent chemotherapy) is at times difficult to quantify as swallowing difficulty can be a late complication developing years after therapy.",
"     </li>",
"     <li>",
"      A retrospective analysis of patients treated with hyperfractionated RT and concurrent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and 5-FU demonstrated on multivariate analysis that the duration of &ge;grade 2 mucositis was predictive (p&lt;0.01) for stricture [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series, 24 patients with head and neck squamous cancer of unknown primary were treated with IMRT to the neck, including concurrent chemotherapy in 22 (92 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/79\">",
"       79",
"      </a>",
"      ]. The median dose to the esophageal mucosa was 60 Gy. With a median follow-up of two years, 11 patients (46 percent) had required esophageal dilatation for a stricture.",
"     </li>",
"     <li>",
"      A retrospective, case control series compared 70 patients with head and neck cancer who developed an esophageal stricture following RT without concurrent chemotherapy with 66 matched controls treated in the same way [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/80\">",
"       80",
"      </a>",
"      ]. The 70 patients with strictures represented approximately 3 percent of all patients treated with RT during the period of the study. Factors associated with a significantly increased risk of esophageal stricture included the need for a percutaneous endoscopic gastrostomy (PEG) tube",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nasogastric tube during treatment, and the use of a radiation dose greater than 45 Gy to the upper esophagus.",
"     </li>",
"     <li>",
"      Advanced tumors of the hypopharynx and larynx that require surgical manipulation of the esophageal verge have increased rates of esophageal toxicity with surgery alone [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/81\">",
"       81",
"      </a>",
"      ] and with surgery followed by postoperative radiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less severe esophageal toxicity may be even more frequent. In a prospective series, 100 patients who had finished all treatment at least three months earlier underwent transnasal esophagoscopy as part of their routine surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/74\">",
"     74",
"    </a>",
"    ]. Overall, some pathology was identified in 87 percent of cases, including peptic esophagitis and stricture in 63 and 23 percent of cases, respectively.",
"   </p>",
"   <p>",
"    Patients with esophageal stricture generally can be managed with dilatation, although frequent repeat procedures may be required, and it is not always effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=see_link\">",
"     \"Management of benign esophageal strictures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822622\">",
"    <span class=\"h1\">",
"     THYROID DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of thyroid disease following RT for head and neck cancer varies widely but appears to be dose-dependent. In a systematic review of the literature that included 971 patients in five studies, most of whom had been radiated for head and neck cancer, the incidence of subclinical and clinical hypothyroidism varied from 26 to 53 and 11 to 33 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Irradiation of the low neck can cause direct damage to the thyroid gland resulting in primary hypothyroidism. This is usually detected by an elevation in serum TSH and is clinically significant in only a minority of cases. Cases of hypothyroidism that are caused by damage to the hypothalamus or pituitary region (central hypothyroidism) are significantly less common [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"     \"Central hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RT-induced hypothyroidism develops at a median of 1.4 to 1.8 years after therapy (range 0.3 to 7.2 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. It is more common in patients undergoing both neck surgery and RT. Some reports have observed a higher rate of hypothyroidism in patients treated using intensity-modulated RT (IMRT); however, this increased risk can be avoided with appropriate technique that minimizes the dose of radiation to the thyroid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/87\">",
"     87",
"    </a>",
"    ]. The incidence of hypothyroidism does not appear to be higher in patients who are managed with chemoradiotherapy compared with RT alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link&amp;anchor=H8#H8\">",
"     \"Disorders that cause hypothyroidism\", section on 'latrogenic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients treated with neck RT, emphasis is generally placed on posttreatment screening and thyroid hormone replacement rather than prevention. A single institution analysis of pediatric patients suggested that TSH suppression during RT had a &ldquo;protective effect&rdquo; on thyroid function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/88\">",
"     88",
"    </a>",
"    ], but this needs to be confirmed on a larger scale before it can be recommended. Currently expert groups recommend that serum TSH should be checked within 12 months of completing therapy and repeated every 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058958059\">",
"    <span class=\"h1\">",
"     MYELITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation damage to the spinal cord is one of the most feared complications of the treatment of cancer with RT. As such, cooperative group trials generally prioritize spinal cord avoidance over target coverage in IMRT planning.",
"   </p>",
"   <p>",
"    The syndrome of radiation myelitis usually begins 9 to 15 months after the end of RT with paresthesias and other sensory disturbances. It then progresses steadily to involve motor signs. It is fatal in approximately 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/91\">",
"     91",
"    </a>",
"    ]. In an analysis of 1112 patients who were treated prior to CT-based planning, 0.18 percent of patients developed radiation myelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/92\">",
"     92",
"    </a>",
"    ]. Current CT based planning techniques, where dose is limited to extremely small volumes, are expected to cause even lower incidences of this feared complication. There is no successful treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7190?source=see_link&amp;anchor=H3#H3\">",
"     \"Complications of spinal cord irradiation\", section on 'Late radiation-induced myelopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A transient phenomenon related to both cervical cord irradiation and platinum containing chemotherapy drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is Lhermitte&rsquo;s sign, known as the &ldquo;barber&rsquo;s chair sign&rdquo;. Lhermitte&rsquo;s sign is characterized by an electric shock sensation that radiates down the spine and extremities on flexion of the neck. It rarely progresses to radiation myelopathy and is typically self-limited in nature. The typical latency is two to four months after the completion of RT. No specific treatment exists, although a soft cervical collar can reduce the flexion of the cervical spine and reduce symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7190?source=see_link&amp;anchor=H2#H2\">",
"     \"Complications of spinal cord irradiation\", section on 'Early radiation-induced myelopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link&amp;anchor=H10#H10\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Myelotoxicity (Lhermitte's sign)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058958074\">",
"    <span class=\"h1\">",
"     RETINOPATHY AND OPTIC NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced optic neuropathy is caused by radiation-induced ischemia to the optic nerve. It is a primary concern for treatment of tumors of the nasopharynx, nasal cavity, and paranasal sinuses that frequently require doses greater than 54 Gy to the optic apparatus (optic nerves, retina, optic chiasm). A sophisticated analysis of radiation parameters affecting radiation-induced optic neuropathy demonstrated that the incidence increases significantly with doses greater than 50 Gy. Protective measures that seem to reduce the incidence are daily fraction sizes &le;1.8 Gy or twice daily fractionation, which seems to be the most protective, particularly at high (eg, &ge; 60 Gy) doses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/94\">",
"     94",
"    </a>",
"    ]. In some instances, treatment of paranasal sinus tumors will require that portions of the retina exceed this threshold. However, CT-based treatment planning in these cases may allow dose-sparing of the macula to preserve central vision. The effect of concurrent chemotherapy is unclear, as its use was rare in this analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H32#H32\">",
"     \"Complications of cranial irradiation\", section on 'Optic neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of therapeutic options for radiation-induced optic neuropathy have been tried. These include corticosteroids, hyperbaric oxygen (HBO), and optic nerve sheath fenestration. It appears that corticosteroids and hyperbaric oxygen work infrequently [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/95\">",
"     95",
"    </a>",
"    ] and that optic nerve fenestration not only does not work but may actually be harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058958082\">",
"    <span class=\"h1\">",
"     OTOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both ionizing radiation and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    can cause sensorineural hearing loss regardless of other comorbidities. When combined, toxicity can be additive [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inner ear apparatus lies in the petrous portion of the temporal bone and should be contoured as an avoidance structure for RT planning [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/94\">",
"     94",
"    </a>",
"    ]. A detailed radiation dosimetric analysis demonstrated that the incidence of sensorineural hearing loss was related to radiation dose [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/98\">",
"     98",
"    </a>",
"    ]. The cochlea is such a small structure that it is generally evaluated as a mean dose function; mean dose less than 45 Gy is typical in cooperative group trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H36#H36\">",
"     \"Complications of cranial irradiation\", section on 'Ototoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most active chemotherapy agent used in the head and neck cancer,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , is associated with significant ototoxicity independent of concurrent RT. Cisplatin ototoxicity is dependent on both cisplatin dose and scheduling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link&amp;anchor=H7#H7\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Ototoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and radiation lowers the radiation dose that causes sensorineural hearing loss. In a retrospective analysis, patients treated with radiation alone could receive up to 40 Gy to the inner ear without measurable hearing impairment. By contrast, concomitant cisplatin caused detectable hearing loss at doses as low as 10 Gy. High dose cisplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) was noted to cause significantly more ototoxicity than low dose weekly cisplatin (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/99\">",
"     99",
"    </a>",
"    ]. A recent analysis has proposed that inner ear radiotherapy constraints should be based upon the number of cycles of cisplatin received [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    is a platinum containing compound that has been used concurrently with head and neck cancer. It is the standard of care for concurrent therapy after induction chemotherapy with TPF (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , 5-FU). Carboplatin is associated with less ototoxicity than cisplatin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment induced ototoxicity can range from tinnitus to sensorineural hearing loss. Its treatment is case specific. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25495?source=see_link\">",
"     \"Treatment of tinnitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058958089\">",
"    <span class=\"h1\">",
"     LACRIMAL GLAND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dry eye syndrome is a disorder that results from deficiencies or defects in the components of lubrication that can lead to structural and functional abnormalities of the ocular surface. Mild to moderate dry eye syndrome responds to conservative measures, but severe dry eye syndrome can cause a multitude of symptoms including compromised vision, severe pain, and eye loss. Therapeutic RT doses to the entire globe can cause severe dry eye syndrome. It appears this is dose dependent. A recent analysis demonstrated that a mean dose &lt;34 Gy to the lacrimal gland limits the incidence of severe dry eye syndrome to less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H33#H33\">",
"     \"Complications of cranial irradiation\", section on 'Xerophthalmia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058958104\">",
"    <span class=\"h1\">",
"     DYSPHONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphonia can be caused by treatment of head and neck cancer when the larynx is targeted by RT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical instruments (ie, laryngeal cancer) and when the larynx is in close proximity to targets (ie, neck lymphatics).",
"   </p>",
"   <p>",
"    Dysphonia after treatment for laryngeal cancer depends on the modality used for primary treatment. Patients with early, superficial T1a larynx cancers have comparable voice quality following treatment with either surgery or RT. Tumors with more than superficial depth of invasion likely have a better functional outcome after primary RT compared with those treated with surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/103\">",
"     103",
"    </a>",
"    ]. Patients with advanced laryngeal cancer seem to have low rates of moderate speech impairment two years after completion of organ preservation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/66\">",
"     66",
"    </a>",
"    ]. Patients who note voice impairment after treatment for early glottic carcinoma benefit from voice therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients receiving either elective or therapeutic nodal irradiation should have the larynx contoured and avoided, as toxicity is dose-related [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/105\">",
"     105",
"    </a>",
"    ]. With careful treatment planning, the ability to limit mean dose to the larynx is similar among different RT techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with all these symptoms, new or worsening dysphonia should raise suspicion for recurrent disease or a second primary cancer of the upper aerodigestive tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3822715\">",
"    <span class=\"h1\">",
"     SMOKING CESSATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with head and neck cancer should receive counseling about the importance of smoking cessation. Besides being a major risk factor, smoking can also influence cancer prognosis. When smoking is continued during and after RT, it can increase the severity and duration of mucosal reactions, exacerbate xerostomia, and compromise oncologic outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study, for example, evaluated 115 patients who were treated with RT with or without 5-fluorouracil (5-FU) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/108\">",
"     108",
"    </a>",
"    ]. The 53 patients who continued to smoke during RT had significantly lower rates of complete response (45 versus 74 percent) and two year survival (39 versus 66 percent) compared with the 62 patients who did not smoke or who had quit before treatment. Among nonsmoking patients, mortality rate was influenced by the duration since quitting smoking. Compared to patients who continued to smoke, the death rate was 40 percent lower in patients who had quit less than 12 weeks before and 70 percent lower in patients who had quit more than one year before diagnosis.",
"   </p>",
"   <p>",
"    Although the epidemiology of head and neck cancer is changing with the emergence of HPV associated oropharyngeal cancer, the importance of smoking cessation has not changed. In an unplanned analysis of RTOG 01-29, the mortality in the HPV positive group was higher for smokers compared with nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17145415\">",
"    <span class=\"h1\">",
"     POSTTREATMENT DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death from non-cancer causes is an important event in head and neck cancer. Improved disease control and increased toxicity have made competing mortality an increasingly important concept in both head and neck cancer treatment and protocol development. An evaluation of almost 500 patients treated with organ preserving chemotherapy, radiotherapy, and surgery on consecutive prospective clinical trials demonstrated a five-year non-cancer cumulative competing mortality incidence of 19.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/110\">",
"     110",
"    </a>",
"    ]. A similar study of competing mortality using the SEER database demonstrated similar mortality rates secondary to cancer recurrence and competing risks (23.8 and 27.6 percent at five years, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/42/30378/abstract/111\">",
"     111",
"    </a>",
"    ]. Attempts were made in both analyses to determine factors predictive of competing mortality; only increasing age was found to be significant in both analyses.",
"   </p>",
"   <p>",
"    It is important to understand issues surrounding competing mortality in modern head and neck cancer therapy. Predictive factors have been suggested. Analysis of competing risks may become prominent in clinical trial development and risk stratification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H707301933\">",
"    <span class=\"h1\">",
"     SECOND MALIGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with head and neck cancer are at increased risk for the development of second malignancies, both in the head and neck and elsewhere. In large part this is due to the same risk factors associated with the initial malignancy (tobacco, alcohol, human papillomavirus). In addition, RT used to treat the primary tumor may contribute to an increased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=see_link&amp;anchor=H5#H5\">",
"     \"Second primary malignancies in patients with head and neck cancers\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616615828\">",
"    <span class=\"h1\">",
"     REHABILITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional rehabilitation is an important component of patient management and can be essential for an optimal outcome following treatment. These issues are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16231?source=see_link\">",
"       \"Alaryngeal speech rehabilitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=see_link\">",
"       \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H707301827\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of head and neck cancers can result in a wide range of late toxicities that have a significant impact on the patient&rsquo;s quality of life. Potential approaches to preventing the development of such toxicities that are applicable during the initial treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Xerostomia",
"      </strong>",
"      &ndash; The most common long-term complication of RT and chemoradiotherapy for head and neck cancer is xerostomia, which is the result of damage to the salivary glands. The use of contemporary conformal radiation therapy (RT) techniques to minimize exposure of the salivary glands to radiation is the most important factor in the prevention of permanent salivary gland damage. For patients with symptomatic xerostomia, treatment approaches include lifestyle modification (moist soft foods, humidifiers), saliva substitutes and nonpharmacologic salivary gland stimulants, and pharmacologic stimulation with parasympathomimetic agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12932?source=see_link\">",
"       cevimeline",
"      </a>",
"      ). Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"       amifostine",
"      </a>",
"      , though not often used, may decrease the risk of permanent xerostomia. (See",
"      <a class=\"local\" href=\"#H3822348\">",
"       'Salivary gland damage and xerostomia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H722454151#H722454151\">",
"       \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Osteoradionecrosis",
"      </strong>",
"      &ndash; Osteoradionecrosis is defined as the presence of a non-healing area of exposed necrotic bone after RT in the absence of recurrent or residual tumor. The primary risk factors associated with the development of osteoradionecrosis are dental extractions and surgery. Compromised teeth in an area that will receive at least 50 Gy and teeth that are outside of the RT treatment field but have a hopeless prognosis should be extracted prior to the initiation of therapy. There is no indication to extract health teeth. After therapy, routine dental care and supplemental fluoride are recommended.",
"      <br/>",
"      <br/>",
"      For mild cases of osteoradionecrosis, treatment with conservative debridement and antibiotics, is usually sufficient. For more advanced cases of bone and soft tissue necrosis, extensive, resection of the mandible with immediate microvascular reconstruction may provide better results. (See",
"      <a class=\"local\" href=\"#H3822453\">",
"       'Osteoradionecrosis and soft tissue necrosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Dysphagia and esophageal toxicity",
"      </strong>",
"      &ndash; Dysphagia and esophageal toxicity are multifactorial complications of head and neck cancer therapy. Contemporary prospective trials demonstrate long term gastrostomy tube rates of 10 percent; however, the true incidence is likely underreported as the development of this toxicity can be many years after treatment and insidious in nature. Careful attention to minimizing radiation to pharyngeal constrictors appears to be helpful in minimizing these complications. (See",
"      <a class=\"local\" href=\"#H975123942\">",
"       'Dysphagia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3822602\">",
"       'Esophageal toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Other toxicities",
"      </strong>",
"      &ndash; There are a wide range of other toxicities that can be seen, depending upon the specific tissues irradiated and the dose of radiation received. These can include injury to soft tissues of the head and neck (trismus, fibrosis in the neck), hypothyroidism, carotid artery injury, various forms of neurologic toxicity (myelitis, optic neuropathy and retinopathy, ototoxicity), and second malignancies. (See appropriate sections above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/1\">",
"      Deasy JO, Moiseenko V, Marks L, et al. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys 2010; 76:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/2\">",
"      Braam PM, Roesink JM, Moerland MA, et al. Long-term parotid gland function after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/3\">",
"      Morton RP, Thomson VC, Macann A, et al. Home-based humidification for mucositis in patients undergoing radical radiotherapy: preliminary report. J Otolaryngol Head Neck Surg 2008; 37:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/4\">",
"      Sciubba JJ, Goldenberg D. Oral complications of radiotherapy. Lancet Oncol 2006; 7:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/5\">",
"      Jensen SB, Pedersen AM, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 2010; 18:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/6\">",
"      Davies AN, Shorthose K. Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. Cochrane Database Syst Rev 2007; :CD003782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/7\">",
"      Chambers MS, Posner M, Jones CU, et al. Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 68:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/8\">",
"      Chambers MS, Jones CU, Biel MA, et al. Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia. Int J Radiat Oncol Biol Phys 2007; 69:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/9\">",
"      Johnstone PA, Peng YP, May BC, et al. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 2001; 50:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/10\">",
"      Wong RK, James JL, Sagar S, et al. Phase 2 results from Radiation Therapy Oncology Group Study 0537: a phase 2/3 study comparing acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating early radiation-induced xerostomia. Cancer 2012; 118:4244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/11\">",
"      Simcock R, Fallowfield L, Monson K, et al. ARIX: a randomised trial of acupuncture v oral care sessions in patients with chronic xerostomia following treatment of head and neck cancer. Ann Oncol 2013; 24:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/12\">",
"      Forner L, Hyldegaard O, von Brockdorff AS, et al. Does hyperbaric oxygen treatment have the potential to increase salivary flow rate and reduce xerostomia in previously irradiated head and neck cancer patients? A pilot study. Oral Oncol 2011; 47:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/13\">",
"      Hong CH, Nape&ntilde;as JJ, Hodgson BD, et al. A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer 2010; 18:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/14\">",
"      Duke RL, Campbell BH, Indresano AT, et al. Dental status and quality of life in long-term head and neck cancer survivors. Laryngoscope 2005; 115:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/15\">",
"      Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 1983; 41:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/16\">",
"      Peterson DE, Doerr W, Hovan A, et al. Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies. Support Care Cancer 2010; 18:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/17\">",
"      Mendenhall WM. Mandibular osteoradionecrosis. J Clin Oncol 2004; 22:4867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/18\">",
"      Chopra S, Kamdar D, Ugur OE, et al. Factors predictive of severity of osteoradionecrosis of the mandible. Head Neck 2011; 33:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/19\">",
"      Cheng SJ, Lee JJ, Ting LL, et al. A clinical staging system and treatment guidelines for maxillary osteoradionecrosis in irradiated nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2006; 64:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/20\">",
"      Douglas JG, Koh WJ, Austin-Seymour M, Laramore GE. Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg 2003; 129:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/21\">",
"      Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 2007; 25:4800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/22\">",
"      Kramer NM, Horwitz EM, Cheng J, et al. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck 2005; 27:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/23\">",
"      Eisbruch A, Harris J, Garden AS, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 2010; 76:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/24\">",
"      Ben-David MA, Diamante M, Radawski JD, et al. Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys 2007; 68:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/25\">",
"      Wendt CD, Peters LJ, Delclos L, et al. Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy. Int J Radiat Oncol Biol Phys 1990; 18:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/26\">",
"      Marx RE, Ames JR. The use of hyperbaric oxygen therapy in bony reconstruction of the irradiated and tissue-deficient patient. J Oral Maxillofac Surg 1982; 40:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/27\">",
"      Pitak-Arnnop P, Sader R, Dhanuthai K, et al. Management of osteoradionecrosis of the jaws: an analysis of evidence. Eur J Surg Oncol 2008; 34:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/28\">",
"      Shaha AR, Cordeiro PG, Hidalgo DA, et al. Resection and immediate microvascular reconstruction in the management of osteoradionecrosis of the mandible. Head Neck 1997; 19:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/29\">",
"      Hao SP, Chen HC, Wei FC, et al. Systematic management of osteoradionecrosis in the head and neck. Laryngoscope 1999; 109:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/30\">",
"      Notani K, Yamazaki Y, Kitada H, et al. Management of mandibular osteoradionecrosis corresponding to the severity of osteoradionecrosis and the method of radiotherapy. Head Neck 2003; 25:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/31\">",
"      Marx RE, Ehler WJ, Tayapongsak P, Pierce LW. Relationship of oxygen dose to angiogenesis induction in irradiated tissue. Am J Surg 1990; 160:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/32\">",
"      Marx RE, Johnson RP, Kline SN. Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. J Am Dent Assoc 1985; 111:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/33\">",
"      Kaur J, Hay KD, Macdonald H, Rich AM. Retrospective audit of the use of the Marx Protocol for prophylactic hyperbaric oxygen therapy in managing patients requiring dental extractions following radiotherapy to the head and neck. N Z Dent J 2009; 105:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/34\">",
"      Sulaiman F, Huryn JM, Zlotolow IM. Dental extractions in the irradiated head and neck patient: a retrospective analysis of Memorial Sloan-Kettering Cancer Center protocols, criteria, and end results. J Oral Maxillofac Surg 2003; 61:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/35\">",
"      Annane D, Depondt J, Aubert P, et al. Hyperbaric oxygen therapy for radionecrosis of the jaw: a randomized, placebo-controlled, double-blind trial from the ORN96 study group. J Clin Oncol 2004; 22:4893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/36\">",
"      Bui QC, Lieber M, Withers HR, et al. The efficacy of hyperbaric oxygen therapy in the treatment of radiation-induced late side effects. Int J Radiat Oncol Biol Phys 2004; 60:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/37\">",
"      Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med 1996; 334:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/38\">",
"      Kanatas AN, Lowe D, Harrison J, Rogers SN. Survey of the use of hyperbaric oxygen by maxillofacial oncologists in the UK. Br J Oral Maxillofac Surg 2005; 43:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/39\">",
"      Delanian S, Chatel C, Porcher R, et al. Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial. Int J Radiat Oncol Biol Phys 2011; 80:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/40\">",
"      Ahn C, Sindelar WF. Bilateral radical neck dissection: report of results in 55 patients. J Surg Oncol 1989; 40:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/41\">",
"      Chua DT, Lo C, Yuen J, Foo YC. A pilot study of pentoxifylline in the treatment of radiation-induced trismus. Am J Clin Oncol 2001; 24:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/42\">",
"      Futran ND, Trotti A, Gwede C. Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations. Laryngoscope 1997; 107:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/43\">",
"      McGarvey AC, Chiarelli PE, Osmotherly PG, Hoffman GR. Physiotherapy for accessory nerve shoulder dysfunction following neck dissection surgery: a literature review. Head Neck 2011; 33:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/44\">",
"      Hartl DM, Cohen M, Juli&eacute;ron M, et al. Botulinum toxin for radiation-induced facial pain and trismus. Otolaryngol Head Neck Surg 2008; 138:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/45\">",
"      Scott AS, Parr LA, Johnstone PA. Risk of cerebrovascular events after neck and supraclavicular radiotherapy: a systematic review. Radiother Oncol 2009; 90:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/46\">",
"      Dorresteijn LD, Kappelle AC, Boogerd W, et al. Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol 2002; 20:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/47\">",
"      Haynes JC, Machtay M, Weber RS, et al. Relative risk of stroke in head and neck carcinoma patients treated with external cervical irradiation. Laryngoscope 2002; 112:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/48\">",
"      Brown PD, Foote RL, McLaughlin MP, et al. A historical prospective cohort study of carotid artery stenosis after radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 2005; 63:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/49\">",
"      Chang YJ, Chang TC, Lee TH, Ryu SJ. Predictors of carotid artery stenosis after radiotherapy for head and neck cancers. J Vasc Surg 2009; 50:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/50\">",
"      Dorth JA, Brizel DM. Incidence of asymptomatic carotid artery stenosis in survivors of head and neck radiation. Int J Radiat Oncol Biol Phys 2011; 81:S76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/51\">",
"      Kozin E, Kapo J, Straton J, Rosielle DA. Carotid blowout management #251. J Palliat Med 2012; 15:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/52\">",
"      Powitzky R, Vasan N, Krempl G, Medina J. Carotid blowout in patients with head and neck cancer. Ann Otol Rhinol Laryngol 2010; 119:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/53\">",
"      Chaloupka JC, Roth TC, Putman CM, et al. Recurrent carotid blowout syndrome: diagnostic and therapeutic challenges in a newly recognized subgroup of patients. AJNR Am J Neuroradiol 1999; 20:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/54\">",
"      McDonald MW, Lawson J, Garg MK, et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys 2011; 80:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/55\">",
"      Bensadoun RJ, Riesenbeck D, Lockhart PB, et al. A systematic review of trismus induced by cancer therapies in head and neck cancer patients. Support Care Cancer 2010; 18:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/56\">",
"      Scott B, D'Souza J, Perinparajah N, et al. Longitudinal evaluation of restricted mouth opening (trismus) in patients following primary surgery for oral and oropharyngeal squamous cell carcinoma. Br J Oral Maxillofac Surg 2011; 49:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/57\">",
"      Dijkstra PU, Kalk WW, Roodenburg JL. Trismus in head and neck oncology: a systematic review. Oral Oncol 2004; 40:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/58\">",
"      Hsiung CY, Huang EY, Ting HM, Huang HY. Intensity-modulated radiotherapy for nasopharyngeal carcinoma: the reduction of radiation-induced trismus. Br J Radiol 2008; 81:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/59\">",
"      Chao KS, Ozyigit G, Blanco AI, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 2004; 59:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/60\">",
"      Chen YY, Zhao C, Wang J, et al. Intensity-modulated radiation therapy reduces radiation-induced trismus in patients with nasopharyngeal carcinoma: a prospective study with &gt;5 years of follow-up. Cancer 2011; 117:2910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/61\">",
"      Melchers LJ, Van Weert E, Beurskens CH, et al. Exercise adherence in patients with trismus due to head and neck oncology: a qualitative study into the use of the Therabite. Int J Oral Maxillofac Surg 2009; 38:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/62\">",
"      Shulman DH, Shipman B, Willis FB. Treating trismus with dynamic splinting: a cohort, case series. Adv Ther 2008; 25:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/63\">",
"      Stubblefield MD, Manfield L, Riedel ER. A preliminary report on the efficacy of a dynamic jaw opening device (dynasplint trismus system) as part of the multimodal treatment of trismus in patients with head and neck cancer. Arch Phys Med Rehabil 2010; 91:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/64\">",
"      Cohen EG, Deschler DG, Walsh K, Hayden RE. Early use of a mechanical stretching device to improve mandibular mobility after composite resection: a pilot study. Arch Phys Med Rehabil 2005; 86:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/65\">",
"      Caglar HB, Tishler RB, Othus M, et al. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/66\">",
"      Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/67\">",
"      Chen AY, Frankowski R, Bishop-Leone J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg 2001; 127:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/68\">",
"      Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26:3582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/69\">",
"      Fua TF, Corry J, Milner AD, et al. Intensity-modulated radiotherapy for nasopharyngeal carcinoma: clinical correlation of dose to the pharyngo-esophageal axis and dysphagia. Int J Radiat Oncol Biol Phys 2007; 67:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/70\">",
"      Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol 2010; 28:2732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/71\">",
"      Chen AM, Li BQ, Lau DH, et al. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2010; 78:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/72\">",
"      Leonhardt FD, Quon H, Abrah&atilde;o M, et al. Transoral robotic surgery for oropharyngeal carcinoma and its impact on patient-reported quality of life and function. Head Neck 2012; 34:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/73\">",
"      Parsons JT, Mendenhall WM, Stringer SP, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer 2002; 94:2967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/74\">",
"      Farwell DG, Rees CJ, Mouadeb DA, et al. Esophageal pathology in patients after treatment for head and neck cancer. Otolaryngol Head Neck Surg 2010; 143:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/75\">",
"      Chen AM, Li BQ, Jennelle RL, et al. Late esophageal toxicity after radiation therapy for head and neck cancer. Head Neck 2010; 32:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/76\">",
"      Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/77\">",
"      Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/78\">",
"      Best SR, Ha PK, Blanco RG, et al. Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. Head Neck 2011; 33:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/79\">",
"      Sher DJ, Balboni TA, Haddad RI, et al. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys 2011; 80:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/80\">",
"      Ahlberg A, al-Abany M, Alevronta E, et al. Esophageal stricture after radiotherapy in patients with head and neck cancer: experience of a single institution over 2 treatment periods. Head Neck 2010; 32:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/81\">",
"      Chone CT, Spina AL, Barcellos IH, et al. A prospective study of long-term dysphagia following total laryngectomy. B-ENT 2011; 7:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/82\">",
"      Vu KN, Day TA, Gillespie MB, et al. Proximal esophageal stenosis in head and neck cancer patients after total laryngectomy and radiation. ORL J Otorhinolaryngol Relat Spec 2008; 70:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/83\">",
"      Boomsma MJ, Bijl HP, Langendijk JA. Radiation-induced hypothyroidism in head and neck cancer patients: a systematic review. Radiother Oncol 2011; 99:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/84\">",
"      Bhandare N, Kennedy L, Malyapa RS, et al. Primary and central hypothyroidism after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 2007; 68:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/85\">",
"      Mercado G, Adelstein DJ, Saxton JP, et al. Hypothyroidism: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma. Cancer 2001; 92:2892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/86\">",
"      Tell R, Lundell G, Nilsson B, et al. Long-term incidence of hypothyroidism after radiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 60:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/87\">",
"      Diaz R, Jaboin JJ, Morales-Paliza M, et al. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010; 77:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/88\">",
"      Massimino M, Gandola L, Collini P, et al. Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor. Int J Radiat Oncol Biol Phys 2007; 69:404.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at www.ncnn.rog (Accessed on August 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/90\">",
"      The development of quality of care measures for oral cavity cancer. Arch Otolaryngol Head Neck Surg 2008; 134:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/91\">",
"      Reagan TJ, Thomas JE, Colby MY Jr. Chronic progressive radiation myelopathy. Its clinical aspects and differential diagnosis. JAMA 1968; 203:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/92\">",
"      Marcus RB Jr, Million RR. The incidence of myelitis after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys 1990; 19:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/93\">",
"      Fein DA, Marcus RB Jr, Parsons JT, et al. Lhermitte's sign: incidence and treatment variables influencing risk after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys 1993; 27:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/94\">",
"      Pacholke HD, Amdur RJ, Schmalfuss IM, et al. Contouring the middle and inner ear on radiotherapy planning scans. Am J Clin Oncol 2005; 28:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/95\">",
"      Roden D, Bosley TM, Fowble B, et al. Delayed radiation injury to the retrobulbar optic nerves and chiasm. Clinical syndrome and treatment with hyperbaric oxygen and corticosteroids. Ophthalmology 1990; 97:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/96\">",
"      Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. JAMA 1995; 273:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/97\">",
"      Low WK, Toh ST, Wee J, et al. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 2006; 24:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/98\">",
"      Bhandare N, Antonelli PJ, Morris CG, et al. Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys 2007; 67:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/99\">",
"      Hitchcock YJ, Tward JD, Szabo A, et al. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 2009; 73:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/100\">",
"      Rao SS, Jackson A, Ming L. Subjective hearing loss (SHL) after chemoradiation for nasopharyngeal and oropharyngeal cancer patients. Int J Radiat Oncol Biol Phys 2011; 81:S179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/101\">",
"      Forestiere AA. Chemotherapy of head and neck cancer. Ann Oncol 1996; 3:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/102\">",
"      Bhandare N, Moiseenko V, Song WY, et al. Severe dry eye syndrome after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 2012; 82:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/103\">",
"      Mendenhall WM, Werning JW, Hinerman RW, et al. Management of T1-T2 glottic carcinomas. Cancer 2004; 100:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/104\">",
"      van Gogh CD, Verdonck-de Leeuw IM, Boon-Kamma BA, et al. The efficacy of voice therapy in patients after treatment for early glottic carcinoma. Cancer 2006; 106:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/105\">",
"      Rancati T, Schwarz M, Allen AM, et al. Radiation dose-volume effects in the larynx and pharynx. Int J Radiat Oncol Biol Phys 2010; 76:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/106\">",
"      Galloway TJ, Amdur RJ, Liu C, et AL.. Revisiting Unnecessary Larynx Irradiation with Whole Neck IMRT. Practical Radiation Oncology 2011; 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/107\">",
"      Rugg T, Saunders MI, Dische S. Smoking and mucosal reactions to radiotherapy. Br J Radiol 1990; 63:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/108\">",
"      Browman GP, Wong G, Hodson I, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 1993; 328:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/109\">",
"      Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/110\">",
"      Mell LK, Dignam JJ, Salama JK, et al. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol 2010; 28:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/42/30378/abstract/111\">",
"      Rose BS, Jeong JH, Nath SK, et al. Population-based study of competing mortality in head and neck cancer. J Clin Oncol 2011; 29:3503.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3365 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30378=[""].join("\n");
var outline_f29_42_30378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H707301827\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3822348\">",
"      SALIVARY GLAND DAMAGE AND XEROSTOMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H707301954\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1058958030\">",
"      Lifestyle modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3822356\">",
"      Saliva substitutes and mucosal lubricants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3822376\">",
"      Stimulation of existing salivary flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3822384\">",
"      - Nonpharmacologic stimuli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3822392\">",
"      - Pharmacologic stimuli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3822400\">",
"      Pilocarpine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3822407\">",
"      Cevimeline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3822414\">",
"      - Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1058958037\">",
"      - Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3822433\">",
"      DENTAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3822453\">",
"      OSTEORADIONECROSIS AND SOFT TISSUE NECROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3822476\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3822484\">",
"      Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3822503\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H975122994\">",
"      - Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H975123001\">",
"      - Pentoxifylline and vitamin E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3822522\">",
"      SOFT TISSUE FIBROSIS IN THE NECK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3822529\">",
"      CAROTID ARTERY INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3822537\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3822557\">",
"      Carotid artery rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3822571\">",
"      TRISMUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H975123942\">",
"      DYSPHAGIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3822602\">",
"      ESOPHAGEAL TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3822622\">",
"      THYROID DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1058958059\">",
"      MYELITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1058958074\">",
"      RETINOPATHY AND OPTIC NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1058958082\">",
"      OTOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1058958089\">",
"      LACRIMAL GLAND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1058958104\">",
"      DYSPHONIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3822715\">",
"      SMOKING CESSATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17145415\">",
"      POSTTREATMENT DEATH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H707301933\">",
"      SECOND MALIGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H616615828\">",
"      REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H707301827\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16231?source=related_link\">",
"      Alaryngeal speech rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17129?source=related_link\">",
"      Clinical manifestations and treatment of radiation-induced fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7190?source=related_link\">",
"      Complications of spinal cord irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=related_link\">",
"      Etiology and classification of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39429?source=related_link\">",
"      Evaluation of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=related_link\">",
"      Second primary malignancies in patients with head and neck cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=related_link\">",
"      Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25495?source=related_link\">",
"      Treatment of tinnitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_42_30379="Adjuv Rx colon CA INT0089";
var content_f29_42_30379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results from United States Intergroup Adjuvant Trial 0089",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        DFS,",
"percent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        OS,",
"percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        5 year",
"       </td>",
"       <td class=\"subtitle2\">",
"        10 year",
"       </td>",
"       <td class=\"subtitle2\">",
"        5 year",
"       </td>",
"       <td class=\"subtitle2\">",
"        10 year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-FU/levamisole",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-FU/high-dose leucovorin",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-FU/low-dose leucovorin",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-FU/leucovorin/levamisole",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DFS: disease-free survival; OS: overall survival; 5-FU: 5-fluorouracil.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Haller D, et al. J Clin Oncol 2005; 23:8671.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30379=[""].join("\n");
var outline_f29_42_30379=null;
var title_f29_42_30380="High fiber diet 1 PI";
var content_f29_42_30380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    High-fiber diet guidelines for children, part 1",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Why we need fiber",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fiber helps children and adults have regular bowel movements and helps prevent constipation and other health problems. Dietary fiber helps keep the bowel and digestive tract healthy and enhances feelings of fullness after eating.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       How much fiber is needed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The recommended intake for dietary fiber is 14 grams/1000 kcals in the diet.* For children, this translates to an intake of about 20 grams/day in early childhood, rising to 29 grams/day for adolescent girls and young women, and 38 grams/day for adolescent boys and young men. To find out the number of grams of fiber in a certain food, read the label, or see the foods listed in this table. High-fiber foods contain 3 or more grams of fiber per serving.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       How to help your child eat more fiber",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       A high-fiber diet should be a balanced diet with foods fromall the food groups. The most common sources of fiber are whole grain breads and cereals, legumes and nuts, fruits, and vegetables. Include these in your child's balanced diet:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Offer your child a variety of high-fiber foods during the day rather than giving only one or two high fiber foods.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Mix a high-fiber cereal with a cereal your child likes.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Offer fresh fruits with the skin on. Prunes and pears act as natural laxatives.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Offer raw vegetables, such as carrots, jicama, or cherry tomatoes for snacks and with meals. Offer a salad with dark green lettuce each day.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Use whole-wheat bread or white bread with added fiber, brown rice, whole-wheat crackers, bran muffins, barley, bran cereals, or oatmeal. Use less refined white flour bread, cereal, and other starches.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Offer 4 to 6 ounces of prune, apple, orange, or pear juice each day. Remember that fresh fruit has more fiber than juice.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Offer snacks that have fiber, like granola bars, fruit bars, fig cookies, or popcorn (after age 3 years).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Help your child develop a taste for bran. Try to include 2 to 4 tablespoons of some form of bran each day.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Add nuts or seeds to breads and salads, or use them as a snack. This is not recommended for children younger than three years.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Preventing constipation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If your child is constipated, follow the dietary guidelines above. Also, encourage your child to drink at least 4 to 8 cups (32 to 64 ounces) of fluid per day, preferably water, low-fat milk, and low-sugar decaffeinated beverages.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These guidelines are continued.",
"    <div class=\"footnotes\">",
"     * Dietary Guidelines for Americans 2005. US Department of Health and Human Services. Available at: www.health.gov/dietaryguidelines/pubs.htm.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30380=[""].join("\n");
var outline_f29_42_30380=null;
var title_f29_42_30381="Differentiation of ThO cells";
var content_f29_42_30381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Differentiation of helper T cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 244px; height: 279px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When antigen is presented by antigen-presenting cells (APCs) to Th0 lymphocytes, Th0 cells may differentiate into either Th1 or Th2 subtypes. In humans, Th1 cells are characterized by the presence of interferon-gamma (IFN-g) and tumor growth factor beta (TGF-b), whereas Th2 cells express IL-4, IL-5, and IL-9. Both sets of human lymphocytes express IL-2, IL-3, IL-10, IL-13, and GM-CSF. Th1 cells induce macrophage activation and granuloma formation. Th2 cells induce atopy and promote IgE, mast cell, and eosinophil production. This fundamental division in T cells appears to correlate with the phenotypic expression of various human diseases.",
"    <div class=\"footnotes\">",
"     NO: nitric oxide; DTH: delayed-type hypersensitivity.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baraniuk, JN, Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997; 99:S764. Copyright &copy; 1997 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30381=[""].join("\n");
var outline_f29_42_30381=null;
var title_f29_42_30382="Pathways of fever production";
var content_f29_42_30382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Pathways of fever production",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 443px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Starting from the top left, infectious agents and/or microbial products, as well as cytokines and other inflammatory processes, induce macrophages, endothelial cells, and the reticuloendothelial system to produce and secrete pyrogenic cytokines into the circulation. These pyrogenic cytokines induce the synthesis of prostaglandin E2 (PGE2) in the hypothalamus. In addition, microbial toxins, acting as ligands to the toll-like receptors in the hypothalamus, stimulate the synthesis of PGE2 by the hypothalamus. PGE2 raises the thermostatic set point in the hypothalamus to febrile levels. The vasomotor center sends signals for heat conservation (vasoconstriction) and heat production (shivering). Corticosteroids reduce the peripheral synthesis of pyrogenic cytokines, whereas antipyretics reduce PGE2 levels in the brain.",
"    <div class=\"footnotes\">",
"     TLR: toll-like receptor; IL-1: interleukin-1; IL-6: interleukin-6; TNF: tumor necrosis factor; IFN: interferon; PGE2: prostaglandin E2.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Reuven Porat, MD and Charles A Dinarello, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30382=[""].join("\n");
var outline_f29_42_30382=null;
var title_f29_42_30383="Age distribution in HL";
var content_f29_42_30383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Bimodal age distribution of Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 504px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Age-specific average annual incidence rates of Hodgkin lymphoma for all races by sex per 100,000 population, 2004 to 2008, in the SEER program. Two peaks are noted: a larger peak in young adults, and a second peak in older adults.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: National Cancer Institute. SEER Cancer Statistics Review 1975-2008. Surveillance Epidemiology and End Results. file://seer.cancer.gov/csr/1975_2008/index.html (Accessed February 16, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_42_30383=[""].join("\n");
var outline_f29_42_30383=null;
